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Exosomen gelten als wichtigste interzelluläre Kommunikatoren und Tetraspanine bzw. 
Tetraspaninkomplexe spielen hierbei eine große Rolle in der exosomalen Erkennung von 
Zielzellen. Es konnte gezeigt werden, dass Exosomen welche einen Tspan8-CD49d 
Komplex tragen bevorzug an Endothelzellen binden, wodurch Angiogenese ausgelöst 
wird. Dieser Befund war unerwartet, da in den Exosomen freisetzende Zellen Tspan8 
mit CD49c und den Tetraspaninen CD9 sowie CD151 assoziiert ist. In Betracht des 
möglichen therapeutischen Nutzens von Exosomen als Botschafter und 
Medikamententransporter, ist es essentiell den genauen Mechanismus der Bildung des 
Tspan8-Netzwerkes in der Zellmembran gegenüber dem der Exosomen zu klären. Daher 
habe ich den Weg der Internalisierung von Tspan8 und Tspan8-Chimären, bei denen der 
N- und/oder C-Terminus gegen die korrespondierenden Regionen von CD9 oder CD151 
ausgetauscht wurden, untersucht. 
Nach Aktivierung der Zelle läuft die Tspan8-Internalisierung schneller ab als die CD9-
Internalisierung und der Tspan8-CD9-CD151-Komplex in der Membran der ruhenden 
Zellen löst sich hierbei auf. Für die Tspan8-Internalisierung ist die Bindung seiner N-
terminalen Region mit Intersectin-2, welches Teil eines multimodularen Komplexes, der 
in die Internalisierung von Clathrin-coated pits involviert ist, essentiell. Die 
Internalisierung und das Recycling von Tspan8 in frühen Endosomen wird durch die 
Rekrutierung von CD49d soweit verstärkt, dass lediglich in mit PMA aktivierten Zellen 
ein Tspan8-INS2-CD49d-Clathrin-Komplex in den cholesteroldepletionsresistenten 
Membranmicrodomänen gefunden werden kann. Die PMA-induzierte Tspan8-
Internalisierung führt zu höherer Zellmigration, jedoch zu verminderter Matrix-Zell- und 
Zell-Zelladhäsion.  
Unter der Annahme, dass dieser Mechanismuns der Tspan8-Internalisierung sowohl zum 
exosomalen Tspan8-Netzwerk, als auch zu den spezifischen Eigenschaften Tspan8-
exprimiernder Exosomen beiträgt, führte ich eine komparative Analyse des exosomalen 
Tetraspanin-Netzes durch, um exosomale Zielzellen zu identifizieren. 
Co-Immunopräzipitation von Zelllysaten und Exosomen aus den 4 Ratten-Tumorlinien 
AS, AS-Tspan8, AS-Tspan8/CD9n und AS-Tspan8/CD104, welche CD9, CD81, CD151 
Zusammenfassung  X   
 
und die CD49c- und CD49d-Integrinketten exprimieren, sich aber in der Expression von 
Tspan8 und von der Integrinkette CD104 unterscheiden, zeigte sowohl im Zelllysat als 
auch im Exosomenlysat, dass CD9, CD81 und CD151 bevorzugt mit CD49c und nur 
CD151 ebenfalls mit CD104 assoziieren. Im Gegensatz hierzu assoziiert Tspan8 im 
Zelllysat mit CD49c, in den Exosomen jedoch mit CD49d und CD104. Die Unterschiede 
in der Zusammensetzung der Komplexe auf Exosomen beeinflusst die Zielzellspezifität 
in vitro und in vivo. In Vivo zeigte sich eine effiziente Aufnahme von Exosomen in 
verschiedene hämatopoetische Kompartimente und Organe nach i.v. Injektion in Ratten. 
Den Tspan8-CD49d Komplex  exprimierende Exosomen integrierten bevorzugt in 
Endothelzellen und Pankreasgewebe, solche die den CD151-CD104 oder den Tspan8-
CD104 Komplex trugen, wurden bevorzugt von stromalen Zellen der Leber und Lunge 
aufgenommen, und CD9- oder CD81-CD49c Komplexe exprimierende Exosomen 
wurden überwiegend in hämatopoetischen Zellen gefunden.  
Zusammenfassend konnte ich den Weg der Tetraspanin8-Internalisierung aufklären und 
zeigen, dass sich veränderte Komplexzusammensetzungen während der Internalisierung 
bilden und in den Exosomen bestehen bleiben. Des Weiteren sind diese Unterschiede in 
den Tetraspanin-Komplexen für die Selektivität der Exosomen für bestimmte Zielzellen 
verantwortlich. Mit diesen Ergebnissen liegen zum ersten Mal sichere Hinweise auf die 
Rolle der exosomalen Tetraspanine in der Auswahl der Zielzelle vor, so dass die 
Zielzellen von Exosomen an Hand der Tetraspanin-Komplexe, die sie tragen, 
vorhergesagt werden können. Dieses Wissen stellt die Grundlage für die Generierung 
maßgeschneiderter Exosomen für den Transport von Therapeutische Mittel dar. 
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1.  Introduction 
Research so far has given us already a great insight into development and establishment 
of a tumor. Nonetheless, cancer still remains the second leading cause of deaths in the 
western world. Cancer mostly arises from one single cell which undergoes genetic 
malfunction leading to gain of function and/or of over representation of oncogenes or a 
loss of function of tumor suppressor genes. This endows the cancer cell with the 
capability of uncontrolled growth, evading the body‟s immune surveillance, and in some 
cases, metastasizing to new loci in the body. 
Tremendous efforts in the field of tumor cell biology so far have equipped us with vast 
information about early tumor progression and thus give us ample understanding on 
tumor development, diagnosis and developing new treatment strategies. However, we 
still lag in the knowledge of late tumor progression which leads to metastasis which is 
the cause of death in 90% of cancer cases (Mehlen and Puisieux, 2006). A growing 
number of molecules have been already linked to this process, but there is still vast 
scope of understanding underlying mechanisms that enable the tumor cells to 
disseminate from the primary tumor site and settle into new, distant regions in the body 
forming metastasis. 
1.1 Cancer: its development   
Transformation from a normal cell into a tumor cell is a multistep process. To develop 
into a life threatening tumor, a cell has to acquire certain features which reflect genetic 
alterations that provide it with growth advantage and progressive transformation into 
cancer cell (Foulds, 1995). There are six hallmarks defined for metastatic cancer 
formation, namely, self-sufficiency in growth signals, insensitivity to growth-
suppressive signals, evading programmed cell death, unlimited replicative potential, 
sustained angiogenesis and tissue invasion and metastasis (Hanahan and Weinberg, 
2000). There are also some non-classical hallmarks of cancer cells which include: 
genetic instability, evasion of cell senescence, epigenetic alterations of cancer related-
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genes, RNA interference alterations in the expression of cancer related-genes, changes in 
glucose and glutamine metabolism, participation of cancer stem cells in cellular 
proliferation, stromal cell participation in the tumor micro-environment, and changes in 
antigenic presentation and immunosuppression due to cytokines in the tumor micro-
environment (Valdespino-Gomez et al., 2010). In this thesis, I would like to elaborate on 
sustained angiogenesis and tissue invasion and metastasis. 
1.1.1 Sustained angiogenesis 
All cells in a tissue lie within 100µm of a capillary for getting oxygen and nutrients. 
Formation of new tissue requires careful regulation of angiogenesis, the outgrowth of 
new blood vessels. To be able to progress into larger tumor mass, incipient neoplasias 
require developing angiogenic capacity (Bouck et al., 1996; Hanahan and Folkman, 
1996; Folkman, 1997). Angiogenesis is also important for cancer cells to disseminate 
into peripheral blood and form micro metastases (Xie et al., 2009). 
Positive and negative regulators of angiogenesis are carefully balanced and regulated. 
Vascular endothelial growth factor (VEGF) and acidic and basic Fibroblast growth 
factor (FGF1/2) are examples of angiogenesis-initiating signals which bind to cognate 
tyrosine kinase receptors on the surface of endothelial cells (Fedi et al., 1997; Veikkola 
and Alitalo, 1999; Otrock et al., 2008; Hicklin et al., 2005). Thrombospondin-1 and 
Pigment epithelium derived factor (PEDF) on the other hand, provide as inhibitors of 
angiogenesis (Bull et al., 1994; Chen et al, 2009). Cancer cells frequently outbalance the 
inhibitors to shift towards angiogenesis induction (Hanahan and Folkman, 1996; Vacca 
et al., 2000). Indeed, many tumors show upregulation of VEGF and FGF and impaired 
thrombospondin expression (Singh et al., 1995; Volpert et al., 1997). In addition, the 
ECM stores activators and inhibitors, which can be released by proteases that are 
expressed by tumor cells (Whitelock et al., 1996). Several studies have demonstrated the 
importance of sustained angiogenesis for tumor growth (Hanahan and Folkman 1996; 
Folkman 1997; Pan et al., 2007; Miao et al., 2000), and angiogenesis is a tempting target 
for therapeutic intervention. 
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1.1.2 Tissue invasion and metastasis 
Malignant tumors are developed by invasiveness and metastasis, the settlement and 
growth of tumor cells at a distant site which is the cause of 90% of deaths of human 
cancers (Mehlen and Puisieux, 2006).  
First step of metastasis is the dissemination of a tumor cell from the primary site. This 
requires epithelial to mesenchymal transition- like (EMT-like) phenomenon 
(Vernon and LaBonne, 2004; Savagner, 2010) when the expression of adhesion 
molecules goes down and a cell partakes a more migratory phenotype. The onset of 
EMT is associated with loss of cellular polarity, partial to total destabilization of cell–
cell junctions, remodeling and replacement of cytoskeletal components, the onset of cell 
motility and the suppression of apoptosis (Moreno-Bueno, 2008).  
Adhesion to the adjacent cells is lowered by modulation of functions of cell adhesion 
molecules (CAMs) of immunoglobulin, cadherin and integrin families. Most widely 
altered cell- cell interaction involves E-cadherin, which is ubiquitously expressed on 
epithelial cells. In normal cell, coupling via E-cadherin leads to anti-growth signal 
transmission via cytoplasmic contact with β-catenin to intracellular signaling circuits 
which include the Lef/ Tcf transcription factor (Christofori and Semb, 1999). E-cadherin 
function seems to be lost in majority of epithelial cancers, by mechanisms which include 
mutational inactivation of E-cadherin or β-catenin genes, transcriptional repression or 
proteolysis of the extracellular cadherin domain (Christofori and Semb, 1999). Changes 
in the expression levels of CAMs from immunoglobulin superfamily also play an 
important role in invasion and metastasis (Johnson, 1991), a clear example being N-
CAM. In neuroblastoma, small cell lung cancer and Wilm‟s tumor, cells switch 
expression from a highly adhesive isoform of N-CAM to its poorly adhesive isoform 
(Johnson 1991; Kaiser et al, 1996), and there is shown to be an overall reduction in its 
expression in invasive pancreatic and colorectal cancers (Fogar et al., 1997).  
Changes in integrin expression are also evident in invasive and metastatic cancers. By 
novel permutations of the α and β integrin subunits, carcinoma cells facilitate invasion 
by shifting their expression of integrins from the ones that favour the ECM in normal 
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epithelium to other integrins (e.g., α3β1 αVβ3 that preferentially bind the degraded 
stromal components produced by the extracellular proteases (Varner and Cheresh, 1996; 
Lukashev and Werb, 1998). 
Another parameter of the invasive, metastatic capability are the proteases (Arribas et al., 
2005; Trivedi et al., 2009). Cancer cells show upregulation of protease genes e.g. matrix 
metalloproteases (MMPs), downregulation of protease inhibitor (e.g., TIMP) genes and 
inactive zymogen forms are converted to active enzymes. In many cancers, the proteases 
are not released by the cancer cells themselves, but by the conscripted stromal and 
inflammatory cells (Werb, 1997; Rundhaug, 2003). After being released, these proteases 
may be wielded by the cancer cells. For example, several cancer cells induce urokinase 
(uPA) expression in cultured stroma cells, which binds to uPA receptor (uPAR) which is 
expressed on cancer cells (Johnsen et al., 1998). Another factor reported recently to be 
implicated in tumor migration and invasion are the microRNAs e.g. metastasis 
promoting miR-373 and miR-520c (Huang et al., 2008). 
For transportation to secondary sites, cancer cells use the vascular or the lymphatic 
system. To enter the blood vessel, the cancer cell has to pass through the endothelium, a 
process called intravasation. Majority of the cells entering the blood stream die due to 
mechanical stress or immune surveillance (Jakobisiak et al., 2003). It is easier for cancer 
cells to enter the lymphatic system since the lymphatic endothelium has larger gaps 
(Alitalo and Carmeliet, 2002). On reaching the secondary site, the cancer cell is required 
to extravasate out of circulation. This means, the cell has to switch to adhesive 
properties again to be able to get fixed in the new settlement. It then has to adapt to the 
new environment to communicate with it, form cell-matrix and cell-cell contacts and 
acquire all the described capabilities again to form a massive tumor in the new site.  
Working with a rat pancreatic tumor model, we became particularly interested in the 
question of tumor-initiated angiogenesis and metastasis. 
1.2 The BSp73AS cell system 
BSp73 is a spontaneously arisen rat pancreatic adenocarcinoma line. Passaging BSp73 
cells subcutaneously several times revealed that the primary tumor obviously consisted 
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of two sublines/ clones. One of the clones, BSp73AS (AS) displayed very weak 
metastatic capability while the other, BSp73ASML (ASML) exhibited very strong 
metastatic potential (Matzku et al., 1983). Upon intra foot-pad injections in syngenic 
rats, the BSp73AS cells displayed large local tumors, but only reached the draining 
lymph nodes. In contrast to this, ASML cells showed very limited local tumor growth 
and rapidly spread through the lymphatic system to the lung and formed thousands of 
miliary metastases which were fatal for the animals. 
Trying to define the differences between AS and ASML cells that account for the 
metastatic spread, molecules abundantly expressed in ASML cells, but absent in AS 
cells were identified by monoclonal antibodies and tested for their metastasis-promoting 
activity by cDNA transfection of AS cells. Thereby CD44v4-v7 was identified as a 
metastasis-promoting molecule. Instead, transfection with the cDNA of Tspa8 revealed a 
very surprising result. Rats bearing AS-Tspan8 tumors did not develop metastasis, but 
died due to DIC. This observation was particularly unexpected, as ASML cells grow 
miliary tumors due to their inability to induce angiogenesis. Thus, we followed, first that 
the tetraspanin Tspan8 is an angiogenesis inducer and second, that ASML cells likely 
express molecules that hamper Tspan8 initiated angiogenesis. 
Before considering these questions, I briefly want to introduce the family of 
tetraspanins. 
1.3 Tetraspanins 
1.3.1 Structure and expression 
Tetraspanins are small surface proteins that span the membrane four times and thus 
called tetraspanins. What distinguishes them from other proteins with four membrane-
spanning domains is the presence of four hydrophobic, putative transmembrane domains 
(TM1-TM4), forming a small and a large extracellular loop (EC1 and EC2), with short 
intracellular amino and carboxyl tails. ECL2 can be subdivided into a constant region 
and a variable region. The constant region may account for dimerization, and the 
variable region for interactions with non tetraspanins partner molecules like integrins. 
Members of the tetraspanin family typically contain 4 to 6 conserved extracellular 
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cysteines linked with 2 to 3 disulfide bonds (Figure1). Four of these cysteines are 
absolutely conserved in all tetraspanins analyzed to date, including 2 cysteines present in 
a CCG motif, around 28–47 residues after the third transmembrane domain, and another 
cysteine about 11 amino acids before the fourth transmembrane domain. These 
conserved cysteines in the ECL2 are the hallmark of tetraspanins. Tetraspanins also 
typically contain conserved polar residues within transmembrane domains 1, 3, and 4, 
which stabilize the tertiary structure together with several other conserved residues 
(Boucheix & Rubinstein 2001, Berditchevski 2001, Todres et al. 2000, Hemler 2001, 
Stipp et al. 2003). The four transmembrane regions are responsible for intra and 
intermolecular interactions. They play an important role in the biogenesis and in 
tetraspanin-tetraspanin interactions to form the tetraspanin web or tetraspanin enriched 
transmembrane domains (TEMs). The intracellular juxtamembrane regions carry 
cysteine residues which are palmitoylated and are responsible for the tetraspanin-
network formation (Yang et al., 2004). The cytoplasmic carboxy-terminus (c-terminus) 
interacts with cytoskeleton- proteins, signal transduction molecules, e.g., protein kinase 
C (PKC). In many tetraspanins for e.g., CD63, Net-1, CD-82, CD37, Tspan-3, CD151 
the c-terminus contains a tyrosine based sorting motif: Tyr-Xa.a-Xa.a-Φ (YXXΦ), where 
represents any hydrophobic amino acid. This motif can bind to the adaptor proteins AP-
1,-2 and -3 which are part of the Clathrin based sorting machinery (Stipp et al., 2003). 
Most of the tetraspanins are glycosylated and this contributes to the variation in their 
molecular weight from 20- 50kDa (Yunta and Lazo, 2003). Most tetraspanins have N- 
glycosylation in the EC2 domain, with a few exceptions: CD9 is glycosylated in the EC1 
(Boucheix et al., 1991) and CD81 and NET-2 are non-glycosylated (Oren et al., 1990). 
The first characterization of a tetraspanin protein (ME491/CD63) at the sequence level 
appeared in 1988 (Hotta et al. 1988) and the existence of a family of related structures 
was first realized in 1990 (Wright et al. 1990, Oren et al. 1990). Tetraspanins are highly 
conserved proteins, some of them found in organisms as primitive as schistosomes and 
nematodes as well as in mammals.  
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Figure 1. Structure of a prototype tetraspanin molecule, with amino terminal and carboxy-terminal 
intracellular domains. There is a large extracellular loop with 6 conserved cysteine residues (red) including the 
CCG motif, and disulphide bonds. The first and forth transmembrane regions have polar amino acids (green), 
the cytoplasmic domains contain palmitoylation sites (pink) and the carboxy-terminal domain contains a 
sorting motif (blue). Adapted from Nature Reviews (Zoller, 2009) 
Certain tetraspanins have a restricted pattern of expression for example, CD53 is highly 
restricted to leukocytes (Maecker et al., 1997; Horejsi et al., 1991); CD37 is present 
exclusively on B-cells (Schwartz-Albiez et al., 1988); uroplakin on bladder epithelium 
(Walz et al., 1995) and RDS/Peripherin is expressed in the retina (Travis et al., 1991). 
Others, such as the leukocyte differentiation antigens CD81 and CD82, which were 
originally described on hematopoietic cells, can be found on most cultured cells. All 
mammalian cells express some members of the tetraspanin family, with the exception of 
red blood cells, which do not express any (Boucheix et al., 2001).                        
1.3.2 The Tetraspanin web 
Individual tetraspanins can form complexes with a large number of membrane and 
cytosolic proteins that are required for their functions (Hemler, 2005; Andre et al., 2006; 
Levy and Shoham, 2005; Zoller, 2009). Their most prominent non-tetraspanin partners 
are integrins e.g., α3β1, α4β1 and α6β1. Tetraspanins are also shown to associate with 
growth factor receptors (Murayama et al., 2008; Sridhar et al., 2006), G protein coupled 
receptors (GPCRs) and their associated intracellular heterodimeric G-proteins (Little et 
al., 2004), several membrane proteases (ADAM10, TADG-15, and CD26/ dipeptidyl 
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peptidase IV), transmembrane proteins associated with tumor metastasis like CD44 and 
Epithelial cell adhesion molecule (EPCAM) and members of immunoglobulin 
superfamily like EWI-F and EWI-2. Some signal transduction molecules found to 
associate with tetraspanins are Protein kinase C (PKC), type II phosphatidylinositol 4-
kinase (PI4KII) and phospholipase Cγ (PLCγ) (Hemler, 2005; Andre et al., 2006; Zhang 
et al., 2001; Claas et al., 2001). 
Tetraspanin interactions can be classified as type I, II and III interactions depending on 
the strength of detergent required to break these associations, type I interaction being the 
strongest. The type I, direct protein-protein interactions are rare. These include 
tetraspanin homodimers, homotrimers and homotetramers, and heteromeric interactions 
between CD151 and some integrins, and between CD9, CD81, Tetraspanin8 and EWI 







region in the tetraspanin molecules. Most of the tetraspanin-integrin and the tetraspanin-
tetraspanin interactions are type II interactions, and depend on the palmitoylation of 
tetraspanins and possibly the partner proteins. . Such interactions probably initiate in the 
golgi and provide target sequences for the co-associations that may follow 
(Berditchevski et al., 2002; Charrin et al., 2002; Zhou et al., 2004, Zoller, 2009). Type 
III interactions as with kinases, are also stabilized by palmitoylation (Hemler, 2005; 
Levy and Shoham, 2005; Berditchevski, 2002; Charrin, 2002). 
 
Figure 2. The tetraspanin web. The molecules: EWI-F, CD13 and Intersectin2 (ITSN2), integrins, 
EpCAM and GPCRs as part of the Tspan8 web. Modified from Nature Reviews (Zoller, 2009). 
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Besides these primary interactions, tetraspanins also associate with cholesterol and 
gangliosides (Charrin, 2003; Odintsova, 2006) which enable a higher order tetraspanin-
complex formation resulting in microdomains called tetraspanin enriched membrane 
micro-domains (TEMs) and provide a signaling platform (Hemler, 2003; Hemler, 2005). 
1.3.3 Functions 
Owing to the dynamic nature of the tetraspanin microdomains (Devaux, 2004) and the 
reversibility of the palmitoylation status (Bijlmakers and Marsh, 2003; Linder et al., 
2007) of this molecule, tetraspanins are involved in a multitude of biological processes. 
What adds to this divergence is that tetraspanins can either act directly, or as molecular 
facilitators, bringing the actual players in close vicinity. 
Tetraspanins can promote spreading, migration and cable formation on extracellular 
matrices. Tetraspanins carry out these activities by compartmentalization of integrins, 
integrin internalization and recycling, or modulating integrin signaling (Hemler, 2005; 
Stipp et al., 2003; Berditchevski, 2001; Levy and Shoham, 2005, Zoller, 2009). 
Tetraspanins are also supposed to be important in cell adhesion by regulating trafficking 
and biosynthesis of associating integrins e.g. CD151 affects cell adhesion and migration 
on Laminin 5 via integrin α3β1 and α6β4 recycling (Winterwood et al., 2006). It has also 
been shown that loss of CD151 upregulates RhoA activation, loss of actin organization 
at cell-cell junctions and increased actin stress fibres at the basal cell surface. This 
implies that CD151 is also an important regulator of stability of tumor cell-cell 
interactions, potentially through its interaction with integrin α3β1 (Johnson et al., 2009). 
CD151 is also known to regulate tumorigenesis by modulating the communication 
between tumor cells and endothelium, depending on its association with integrin α3β1 
and α6β4. 
Tetraspanins can also modulate cell-migration by their association with or recruitment of 
EWI-1 and-2 proteins which interact with ezrin–radixin–moesin proteins (ERM 
proteins) and down-regulate their phosphorylation. Phosphorylated ERM proteins can 
link the actin cytoskeleton with transmembrane proteins (Sala-Valdes et al., 2006) and 
thus affect cell migration. Tetraspanins also play a role in protein trafficking for e.g., 
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CD63 has been shown to serve as an adaptor protein that links its interaction partners to 
the endocytic machinery (Duffield et al., 2003) association of CD151 with AP-2 which 
participate in endocytosis via the Clathrin coated vesicles (Stipp et al., 2003).  
Several Tspans such as CD9, CD81 and CD82 regulate the activity of ADAM10 towards 
several substrates and illustrate how membrane compartmentalization by Tspans can 
control the function of cell surface proteases such as ectoproteases (Arduise et al., 2008). 
Tspans CD81 and CD82 affect myeloma cell fate via Akt signaling and FoxO activation. 
This anti myeloma effect of CD81/CD82 involves a down regulation of Akt, activation 
of FoxO transcription factors and decrease in mTOR and mTOR/ rictor (Lishner et al., 
2008).   
There are in addition, strong evidences that tetraspanins are also involved in fusion 
process, synaptic contacts at neuromuscular junctions, platelet aggregation, maintenance 
of skin integrity, immune response induction. For example, CD9 knock-out mice were 
infertile (Miyado et al., 2000) since their CD9 null eggs were incapable of fusing with 
sperms. Tetraspanins also have various roles in the life cycle and entry of different 
viruses like human T-cell leukemia virus1 and HCV type 16 (Spoden et al., 2008) in the 
host cell. CD63 was found to be associated with sites of HIV-1 assembly and can be 
found later in the viral membranes (Garcia et al., 2005). Another tetraspanin, CD81 has 
been implicated in the entry of HCV into its natural host cells (Cocquerel et al., 2006).   
1.4 Tetraspanin 8 (Tspan8)  
Tetraspanin 8 (D6.1A in rat and CO-029 in humans) originally was shown to be 
overexpressed in colorectal cancer (Sela et al., 1989) and described as a tumor-
associated antigen in several human cancers (Szala et al., 1990) like colorectal, 
pancreatic and hepatocellular carcinoma (Zoller et al., 2006). 
Tspan8 interacts with other tetraspanins namely, CD9, CD81, CD151 and several 
integrins, including α3β1, α6β1, α4β1. Tspan8 also associates with non-integrin partners 
including EWI-F, EpCAM, CD13 (Claas et al., unpublished observations), PKC and 
PI4KII, EpCAM, CD44v4-v7 and α6β4 (Claas et al., 2005; Claas et al., 1998; Herlevsen, 
2003; Gesierich, 2005).  
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1.4.1 Tetraspanin 8 and tumor progression 
Profiling the tetraspanin web in human colon cancer cells revealed that Tspan8 was 
expressed in two metastatic sub-lines but not in a non-metastatic sub-line (Le Naour et 
al., 2006). High Tspan8 expression in a metastasized cell line SW620 compared to the 
primary tumor-derived colon carcinoma line SW480 from the same patient (Huerta et 
al., 2003) supports a role of Tspan8 in tumor progression. Tspan8 overexpression 
correlates with poor differentiation and intrahepatic metastatic spread of hepatoma, with 
only a hepatoma clone over-expressing Tspan8 developing intrahepatic metastases 
(Kanetaka et al., 2003).  
The connection between Tspan8 and metastasis has been suggested to rely on its motility 
and survival supporting activities. There is strong evidence that Tspan8 promotes 
motility mostly through its association with α6β4. Although not constitutively, Tspan8 
associates with α6β4 after hemidesmosome disassembly, which is accompanied by 
transient internalization of α6β4–CD151 and Tspan8 complexes, changes in cell shape 
towards a migratory phenotype, increased motility and hepatic metastasis formation 
(Huerta et al., 2003; Herlevsen et al., 2003). It is noteworthy that certain integrins are 
continually internalized from the plasma membrane to the endosomal compartment and 
are recycled back to the cell surface within 30 minutes through short-loop recycling 
under the control of RAB4A or through a long recycling loop through the perinuclear 
compartment under the guidance of RAB11A129 (Caswell and Norman, 2006). 
Tspan8 has also been shown to promote migration, invasion and metastasis in 
oesophageal cancer by inducing upregulation of ADAM10 expression, which is a 
membrane anchored disintegrin metalloprotease (Zhou et al., 2004). It has also been 
observed that high expression levels of Tspan8 are associated with increased resistance 
to apoptosis (Huerta et al., 2003; Kuhn et al., 2007), where Tspan8 associated PKC 
probably plays important role (Kuhn et al., 2007; Ladwein et al., 2005). 
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1.4.2 Tspan8 and angiogenesis 
Early works in our lab delivered first hints towards a metastasis-independent activity of 
Tspan8. In line with the metastasis promoting activity of Tspan8, AS cells transfected 
with Tspan8 and β4 showed increased metastatic potential (Herlevsen, 2003). Instead, as 
already mentioned, when AS line transfected with Tspan8 was injected into rats, lethally 
disseminated intravascular coagulation (DIC) developed which could be prevented by 
administration of the Tspan8 specific antibody (Claas et al., 1998). This suggested 
Tspan8 engagement in angiogenesis. DIC is a prothrombic state which is often seen in 
cancer patients, and tumor- associated angiogenesis and leakiness of tumor vessels are 
considered most important for this process (Zoller, 2009). 
Subsequently, it was shown that DIC is a sequel of systemic angiogenesis induction via 
Tspan8 expressing exosomes (Gesierich et al., 2006). It was shown in our lab that 
Tspan8-overexpressing tumor cells induce angiogenesis in vivo, and tumor cells as well 
as exosomes derived thereof profoundly increased endothelial cell branching in vitro. 
Tumor cell-derived Tspan8 stimulates angiogenic factor transcription, which includes 
increased matrix metalloproteinase (MMP13) and urokinase-type plasminogen activator 
secretion, pronounced vascular endothelial growth factor expression in fibroblasts, 
vascular endothelial growth factor receptor (VEGFR) expression, and strong Tspan8 up-
regulation in sprouting endothelium. Thus, Tspan8 initiates an angiogenic loop that, 
probably due to the abundance of Tspan8 in tumor-derived exosomes, reaches organs 
distant from the tumor. The Tspan8-specific antibody blocks angiogenesis effectively 
and with high selectivity for sprouting endothelium, where Tspan8 is highly upregulated 
(Gesierich et al., 2006). 
As already mentioned, the integrin profile of the tumor cell is decisive of whether Tspan 
would induce tumor cell migration/metastasis or angiogenesis. Angiogenesis induction 
dominates in the absence of α6β4, which may actively suppress this process (Gesierich, 
2006). Given that angiogenesis in this model is initiated by tumor cell-derived 
exosomes, the question arose, how Tspan8 may become integrated in exosomes. 
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1.5 Exosomes 
Exosomes are 40–100 nm diameter membranous vesicles of endocytic origin that are 
released by a variety of cell types into the extracellular space (Simpson et al., 2008). 
Inward budding of endosomal membranes results in the progressive accumulation of 
intraluminal vesicles (ILVs) within large multivesicular bodies (MVBs). 
Transmembrane proteins are incorporated into the invaginating membrane while the 
cytosolic components are engulfed within the ILVs (Van Niel, 2006). Based on their 
biochemical properties, intracellular MVBs can either traffic to lysosomes where they 
are subjected to proteosomal degradation i.e., „degradative MVBs‟ or, alternatively, to 
the plasma membrane (PM) where upon fusion with the PM they release their contents 
(ILVs) into the extracellular space, the so-called „exocytic MVBs‟. ILVs released into 
the extracellular space are referred to as „exosomes‟. To date, exosomes are the only 
type of membranous vesicles originating from intracellular compartments such as the 
MVBs. Endosomal Sorting Complexes Required for Transport (ESCRTs), multi-protein 
complexes, are involved in the mechanism governing the biogenesis/degradation of 
MVBs (Babst, 2005; Babst, 2006) in a ubiquitinylation-dependent (Hurley, 2008) 
manner. 
Certain mechanisms for protein sorting to MVBs have been elucidated and include 
ubiquitination of the target and preferential aggregation. As shown in Figure2, Clathrin 
coated pits (include ubiquitinated proteins and proteins with other sorting signals that 
bind to AP-2 or Clathrin associated sorting proteins (CLASPs) (Traub et al., 2007)), 
aggregation of proteins in lipid rafts and TEMs can act as sorting signals to MVBs. A 
key player in MVB biogenesis is the hetero-oligomeric protein complex, endosomal 
sorting complex required for transport (ESCRT). ESCRT-I, -II and -III recognize mono-
ubiquitinated cargoes and promote their inclusion in MVBs (Piper et al., 2007). Once 
completed, the ESCRT complex dissociates from the MVB membrane aided by the 
adenosine triphosphatase vacuolar protein sorting 4 (Vps4) and is recycled for 
subsequent cargo. However, some proteins such as the transferrin receptor are present in 
ILVs but are not ubiquitinated. Some studies also indicate that the transferrin receptor 
can interact with the ESCRT machinery despite the lack of ubiquitination (Geminard et 
al., 2004). These proteins, which lack the sorting signal for ubiquitination, are 
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partitioned into the ILVs based on their intrinsic physical properties and preference to 
segregate into raft-like microdomains (de Gassart et al., 2003). Protein clustering 
appears to be a major determinant in protein trafficking to the MVB. 
 
Figure 3. The generation of exosomes: a, b: Clathrin-coated pits, clustering of proteins in lipid rafts or 
tetraspanin-enriched membrane microdomains (TEMs) act as sorting signals, where endocytosed membrane 
proteins follow several routes from early endosomes (EEs) to recycling endosomes or multivesicular bodies 
(MVBs). MVBs derive from membrane invagination of EEs, the inward budding vesicles being defined as 
intraluminal vesicles. Ubiquitylation, Rab proteins and the endosomal sorting complexes required for 
transport (ESCRT) machinery, among others, are involved in the intracellular transport of the vesicles and 
help to sort cargo into the MVBs. The intraluminal vesicles either fuse with lysosomes for degradation, are 
released in the cytoplasm in a process called back fusion or are delivered as exosomes. Modified from 
Nature reviews (Zoller, 2009). 
Exosome composition varies with the cell of origin. Nonetheless, exosomes contain a 
number of common protein components (Thery et al., 2001). The cytosolic proteins 
present on exosomes include Rabs, which promote exosome docking and the membrane 
fusion events (Mears et al., 2004). The annexins, including annexin I, II, V and VI, may 
regulate membrane cytoskeleton dynamics and membrane fusion events (Futter et al., 
2007). Several adhesion molecules such as intercellular adhesion molecule-1, CD146, 
CD9, milk-fat-globule EGF-factor VIII (MFG-E8), CD18, CD11a, CD11b, CD11c, 
CD166 and LFA- 3/CD58 have also been identified in exosomal preparations (Thery et 
al., 2001; Mears et al., 2004). In addition, several proteins involved in apoptosis e.g., 
thioredoxin peroxidase II, Alix, 14-3-3 and galectin 3, as well as heatshock proteins 
Hsp70 and Hsp90, which can facilitate peptide loading onto major histocompatibility 
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complex (MHC) I and MHCII (Gastpar et al., 2005) are present on exosomes. As 
mentioned, one of the characteristic features of exosomes is the tetraspanins, which 
include CD9, CD63, CD81 and CD82. Exosomes also carry some cell-specific proteins 
like MHCII and CD86 present only on exosomes isolated from antigen-presenting cells 
(APCs) (Segura et al., 2005) and MFG-E8/ lactadherin present on exosomes from 
immature DCs (Veron et al., 2005). They are also enriched in proteins that participate in 
vesicle formation and trafficking like the lysobisphosphatidic acid (LBPA)-binding 
protein Alix (Futter et al., 2007). Other proteins like the metabolic enzymes such as 
peroxidases, pyruvate and lipid kinases and enolase-1 (Hegmans et al., 2004) are also 
detected on exosomes. Consistent with their endosomal origin, exosomes typically do 
not contain endoplasmic reticulum, mitochondria or nuclear proteins. 
1.6 Tetraspanins and Exosomes 
Exosomes have a wide variety of functions such as secretion of some proteins like 
transferrin receptor from red blood cells during maturation; in ectodomain shedding and 
consequently a vehicle for the cellular export of soluble molecules like L1 (CD171) and 
CD44 (Stoeck et al., 2006). Exosomes also play a role in antigen presentation (Wolfers 
et al., 2001) and are also implicated in immune suppression (Peche et al., 2003; Kim et 
al., 2005). Besides other functions exosomes   are abundantly released by tumor cells 
(van Niel, 2006; Fevrier and Raposo, 2004; de Gassart et al., 2004; Lakkaraju et al., 
2008). Exosomes are deemed to be indispensible for intercellular communication by the 
transfer of proteins, mRNA and miRNA in targeted cells, which can have severe 
consequences for the target cell by initiating activation of signaling cascades, inducing 
gene transcription, or RNA silencing (Février and Raposo, 2004; Schorey et al., 2008; 
Simpson et al., 2009; van Niel, 2006). Notably, it is known for long that tetraspanin 
complexes are constitutive components of exosomes (Escola et al., 1998; Hemler, 2003; 
Zoller, 2006). However, whether tetraspanins are functionally relevant components of 
exosomes remained elusive for a long time. We have recently attacked this question in 
the above described model of Tspan8-exosome-induced angiogenesis. First to note, we 
could confirm the striking power of exosomes in intercellular communication (Gesierich 
et al., 2006). AS-Tspan8-derived exosomes significantly altered protein expression and 
RNA transcription in endothelial cells and sufficed not only for EC activation, but also 
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for EC progenitor maturation. Furthermore, the effects of AS-Tspan8-derived exosomes 
on endothelial cells could be inhibited by D6.1 and anti-CD49d, but not by anti-CD151, 
anti-CD9 or anti-CD49c (Nazarenko et al., 2010). These latter findings were somewhat 
surprising as AS-Tsan8 cells express CD9 and CD151 at high levels and Tspan8, CD9 
and CD151 preferentially interact with CD49c rather than CD49d.  
1.7 Aim of the thesis 
As described and expected, AS-Tspan8-derived exosomes mostly affected endothelial 
cells. Though expected, the molecular basis was not at all clear. This also accounted for 
the inefficacy of CD151 and CD9 in angiogenesis induction as well as for the 
contribution of CD49d and the apparent failure of involvement of CD49c. To shed light 
on these open questions, I started to search for peculiarities of Tspan8 recruitment into 
exosomes where the first step will be the internalization and endosomal recovery. 
Tetraspanins can become internalized via a tyrosine-based internalization motif, YxxΦ. 
It is possible that this position close to the membrane disrupts the binding of the μ 
subunit of the AP-2 adaptor complex (Berditchevski, 2007; Nakatsu et al., 2003, Zoller, 
2009). The motif not being present in all tetraspanins (CD9) or being located too close to 
the plasma membrane (Tspan8) (Berditchevski, 2007), tetraspanins may alternatively 
become internalized via associated molecules with an YxxΦ motif (Aridor et al., 2002; 
Xu et al., 2009). CD151 and CD49d both contain a tyrosine-based internalization motif 
(Berditchevski et al, 2007; Bonifacino and Traub, 2003; Pandey et al., 2009). Thus, CD9 
and/or Tspan8 could become internalized via their association with either of these 
molecules. However, because only AS-Tspan8-, but not AS-derived exosomes interact 
with EC (Gesierich et al., 2005; Nazarenko et al., 2010), a common path of Tspan8 and 
CD9 internalization via CD151 and CD49d became unlikely. 
To answer the question, how Tspan8 becomes recruited into exosomes, we sought to 
define the region(s) of Tspan8, which are important for the obviously quite selective 
internalization of Tspan8. To foray into this research, I exchanged the N- and/or the C-
terminal regions of Tspan8 by the corresponding regions of CD9 and CD151 or, the 
large extracellular loop of CD9 and CD151 was exchanged with that of Tspan8.  
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Subsequently, I searched for molecules associating with the internalization-relevant 
Tspan8 regions. This included the exploring how CD49d may come into play. 
On the basis of these results and having unraveled the Tspan8 internalization complex, I 
started to explore the engagement of this internalization and exosomal Tspan8 complex 
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2. Material and Methods 
2.1 Material 
2.1.1 Instruments 
Name  Company 
Agitator for bacterial cultures Edmund Buehler GmbH, Hechingen 
Camera system Spot CCD Diagnostic Instruments, Sterling Heights, USA 
Cell chamber Neubauer improved Brand, Wertheim 
Centrifuge Sorvall RC5B Plus Kendro, USA 
Centrifuge Biofuge fresco Heraeus, Hanau, Hanau 
DNA-agarose gel electrophoresis chamber Bio-Rad, Munich 
Eagle eye (Mididoc) Herolab, Wiesloch 
ELISA plate reader Anthos labtec, Wals, Austria 
FACS  Calibur Becton-Dickinson, Heidelberg 
Hyper processor (for processing films) Amersham, Freiburg 
Incubator for bacteria Melag, Berlin 
Incubator for cell culture Labotec, Goettingen 
Invert microscope DM-IL Leica, Bensheim 
LSM710 (laser scanning microscope) Zeiss, Goettingen 
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Master cycler (PCR cycler) Eppendorf, Hamburg, 
Magnetic stirrer 3000 Heidolph, Keilheim 
Microscope DMBRE Leica, Bensheim 
Microwave Phillips, Wiesbaden 
Photocassette Amersham, Freiburg 
Ph-Meter-761 Calimatic Knick, Berlin 
Photometer Ultraspec III Amersham, Freiburg 
Pipettus-Akku Hirschmann, Eberstadt 
Pipettes Eppendorf, Hamburg 
Powersupply PS 9009 GIBCO, Darmstadt 
Rotor GSA Kendro, USA 
Rotor SW34 Kendro, USA 
Rotor SW41 Ti Beckman Coulter, Krefeld 
Steril bank Heraeus, Hanau 
Sonicator Sonoplus Bandelin, Berlin 
Tabletop centrifuge Heraeus, Hanau 
Transferapparatus Mini Trans-Blot
®
 Bio-Rad, Munich 
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Thermo-mixer Eppendorf, Hamburg 
Ultrasound homogenizer Bandelin Electronik 
Water-bath Julabo, Seelbach 
Weighing scale RC210 D Sartorius, Goettingen 
Whirlmixer Vortex Genie Si Inc., New York, USA 
2.1.2 Miscellaneous Material  




 Greiner, Frickenhausen 
Cell culture 96-well, 24-well, 6-well plates Greiner, Frickenhausen 
Centrifugal concentrators Vivaspin 6ml, 
20ml 
Vivascience, Hannover 
Cryovials Greiner, Frickenhausen 
Coverglass R. Langenbrinck, Emmendingen 
Dako pen DakoCytomat., Glostrup, Denmark 
Electroporation cuvettes Eugentec, Seraing, Belgium 
Falcon tubes 15ml, 50ml Greiner, Frickenhausen 
Glass slides R. Langenbrinck, Emmendingen 
Hyperfilm ECL Amersham, Freiburg 
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Needles BD Biosciences, Heidelberg,  
Nitrocellulose membrane Hybond ECL Amersham, Freiburg 
Parafilm American Nat. Can., Greenwich, Great 
Britain  
Petriplates Greiner, Frickenhausen 
Pipette tips Sarstedt, Numbrecht 
Sterile filter 0,2µm Renner, Darmstadt 
Syringes BD Biosciences, Heidelberg 
Trans-well migration (Boyden) chambers 
48 well 
Neuroprobe, Gaithusberg, USA 
WhatmanTM 3MM paper Scleicher & Schull, Dassel 
2.1.3 Chemicals and Reagents 
Acetic acid Riedel-de Haen, Seelze 
Acetone Fluka, Buchs, Switzerland 
Agarose Sigma, Steinheim 
Ammonium persulphate (APS) GIBCO, Darmstadt 
Ampicillin sulphate Calbiochem, Darmstadt 
Bactoagar Fluka, Buchs, Switzerland 
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Bio-Rad, Munich Bradford reagent Bio-Rad, Munich 
Biotin-X-NHS Calbiochem, Darmstadt 
Bovine Serum Albumin (BSA) PAA, Pasching, Austia 
Brij 96 Fluka, Buchs, Switzerland 
Bromo phenol blue Merck, Darmstadt 
Calcium chloride Merck, Darmstadt 
CFSE Invitrogen, Darmstadt 
Chloroform Riedel-de Haen, Seelze 
Coomassie R-250 Merck, Darmstadt 
Crystal violet Sigma, Steinheim 
Dimethyl formamide Merck, Darmstadt 
Dimethyl sulfoxide (DMSO) Merck, Darmstadt 
Dynasore (dynamin 1 inhibitor)  Santacruz, Heidelberg 
Embedding medium Neg-50 R.-A. Scientific, Kalamanzoo, USA 
Ethanol Riedel-de Haen, Seelze 
Ethidium bromide Merck, Darmstadt 
Ethylenediamine tetraacitic acid (EDTA) Sigma, Steinheim 
Foetal Calf Serum (FCS) PAA, Pasching, Austria 
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Formaldehyde (37%) Merck, Darmstadt 
G418 sulphate  PAA, Pasching, Austria 
Gelatine (cold water fish skin) Merck, Darmstadt 
Glucose Merck, Darmstadt 
L-Glutamine AppliChem, Darmstadt 
Glycerine Roth, Karlsruhe 
Glycine GERBU, Gaiberg 
HEPES GERBU, Gaiberg 
HiPerfect-Reagent for transfection Quiagen, Hilden 
Hydrochloric acid (HCl) Riedel-de Haen, Seelze 
Hygromycin PAA, Pasching, Austria 
Immersion oil Zeiss, Goettingen 
Isopropanol Fluka, Buchs, Switzerland 
Laminin-5 K. Miyazaki, Yokohoma, Japan 
Magnesium carbonate Merck, Darmstadt 
Magnesium chloride Merck, Darmstadt 
Magnesium sulphate Merck, Darmstadt 
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Milk powder Roth, Karlsruhe 
Matrigel (ECM gel) Sigma, Steinheim 
Methanol Riedel-de Haen, Seelze 




Paraformaldehyde Sigma, Steinheim 
Penicillin Sigma, Steinheim 
Phenylmethylsulphonylfluoride (PMSF) Sigma, Steinheim 
Phorbolmyristateacetate (PMA) Sigma, Steinheim 
Potassium acetate Sigma, Steinheim 
Potassium carbonate Roth, Karlsruhe 
Potassium chloride Merck, Darmstadt 
Potassium dihydrogenphosphate Merck, Darmstadt 
Potassium tetrathionate Merck, Darmstadt 
Protease Inhibitor Cocktail Tablets Roche Diagnostics, Mannheim 
Protein G Sepharose 4 Fast Flow Amersham Biosciences, Freiburg  
Rotipherose Gel 30 (Acrylamide-mix) Roth, Karlsruhe 
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Rhodamine DHPE Invitrogen, Darmstadt 
RPMI 1640 GIBCO, Darmstadt cell culture 
Silver nitrate Roth, Karlsruhe 
Sodium acetate Merck, Darmstadt 
Sodium azide AppliChem, Darmstadt 
Sodium carbonate AppliChem, Darmstadt 
Sodium chloride Fluka, Buchs, Switzerland 
Sodium hydrogen phosphate Merck, Darmstadt 
Sodium dodecyl sulphate (SDS) GERBU, Gaiberg 
Sodium hydrogen carbonate AppliChem, Darmstadt 
Sodium hydroxide Riedel-de Haen, Seelze 
Sodium pyruvate Merck, Darmstadt 
Sodium thiosulphate Merck, Darmstadt 
SP-Dio18(3) dye for exosome labeling Invitrogen, Darmstadt 
Tris Roth, Karlsruhe 
Triton-X-100 Sigma, Steinheim 
Trypan bue Serva, Heidelberg 
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Trypsin Sigma, Steinheim 
Trypton AppliChem, Darmstadt 
Tween 20 Serva, Heidelberg 
Yeast Extract GIBCO, Darmstadt  
2.1.4 Standard buffers and solutions 
Bicarbonate buffer 15mM Na2CO3, 35mM NaHCO3, pH 9.6 
Blot buffer  25 mM Tris, 192mM Glycine,0.1% SDS, 20% 
Methanol 
Ethidium Bromide 0.01% (w/v) in water. Store in dark. 
Freezing medium 10% DMSO in FCS 
HEPES buffer 25mM HEPES, 150 mM NaCl, 5mM MgCl2, 1 mM 
PMSF, Protease inhibitors  
6x Laemmli-buffer 350mM Tris, pH6.8, 10% (w/v) SDS, 36% (w/v) 
Glycerine, 0.01% (w/v) Bromophenol blue 
LB medium 10g peptone, 5g yeast extract, 10g NaCl. Make 
volume to 1l. Add 15g agar for LB plates. 
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Running buffer for SDS-PAGE 
(10X) 
1%SDS (w/v), 144g Glycine, 30g Tris. Make volume 
to 1l with bidest water. 
PBS  
 
137 mM NaCl, 8.1mM Na2HPO4, 2.7 mM KCl, 
1.5mM KH2PO4, pH 7.4 
PBG PBS, 0.2% gelatin from fresh water goldfish, 1%BSA 
Stripping / acid wash buffer PBS-HCl pH2.5 
Stripping buffer for western blots 62.5 mM Tris-HCl (pH 6.8), 2% SDS. ,0.1 M 2-
Mecaptoethanol 
TAE buffer  242g Tris base, 57.1ml Glacial acetic acid, 100ml 
0.5M EDTA pH 8.0. Make volume to 1l and adjust 
pH to 8.5 
2.1.5 Enzymes 
Restriction enzymes  MBI Fermentas, St. Leon-Rot 
Taq polymerase MBI Fermentas, St. Leon-Rot 
T4 Ligase MBI Fermentas, St. Leon-Rot 
Calf Intestinal alkaline phosphatase (CIAP) MBI Fermentas, St. Leon-Rot 
2.1.6 Kits 
Quiaquick gel extraction kit QUIAGEN, Hilden 
Quiaquik Midiprep kit QUIAGEN, Hilden 
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ECL Western Blotting Detection Reagents Amersham, Freiburg 
2.1.7     Size markers 
 
GeneRulerTM 100bp DNA-Ladder Plus MBI Fermentas, St. Leon-Rot 
GeneRulerTM 1Kb DNA-Ladder Plus MBI Fermentas, St. Leon-Rot 
PagerulerTM Prestained Protein Ladder MBI Fermentas, St. Leon-Rot 
2.1.8     Antibodies 
2.1.8.1 Primary Antibodies  
Antibody Company 
α6β4 (clone B5.5) Matzku et al., 1989 
CD4 (clone Ox35) 
European Association of Animal Cell 
Cultures 
CD8 (clone Ox8) 
European Association of Animal Cell 
Cultures 
CD9; clone B2C11 
BD Biosciences, Heidelberg; 
Developmental studies Hybridoma bank 
CD11a BD, Heidelberg, Germany 
CD11b (clone Ox42) 
European Association of Animal Cell 
Cultures 
CD11c (clone Ox41) 
European Association of Animal Cell 
Cultures 
CD13 Chang et al, 2005 
CD18 BD Biosciences, Heidelberg 
CD29; (clone FW4.10.1) 
BD Biosciences, Heidelberg, 
Developmental studies Hybridoma bank 
CD31 BD, Heidelberg, Germany 
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CD44 (clone Ox50) European Association of Animal Cell 
Cultures 
CD44v6 (clone A2.6) Matzku et al., 1989 
CD49c ; clone Ralph3.1 
BD Biosciences, Heidelberg, 
Developmental studies Hybridoma bank 
CD49d BD Biosciences, Heidelberg 
CD49e BD Biosciences, Heidelberg 
CD49f Abcam, Cambridge, U.K 
CD54 BD Biosciences, Heidelberg 
CD56 BD Biosciences, Heidelberg 
CD61 BD Biosciences, Heidelberg 
CD62L BD Biosciences, Heidelberg 
CD63 BD Biosciences, Heidelberg 
CD81 BD Biosciences, Heidelberg 
CD104 BD Biosciences, Heidelberg 
CD106 BD Biosciences, Heidelberg 
CD151 Claas et al., 2005 
Caveolin BD Biosciences, Heidelberg 
Clathrin Calbiochem, Darmstadt 
D6.1 Matzku et al., 1998 
EWI-F Orlicky et al., 1998 
ISN2 Santa Cruz, Heidelberg, Germany 
Lamp1 BD Biosciences, Heidelberg 
rab5 BD Biosciences, Heidelberg 
rab7 Santa Cruz, Heidelberg, Germany 
Transferrin receptor  (Ox26) 
European Collection of Animal  Cell 
Culture 
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2.1.8.2 Secondary Antibodies and Reagents 
Anti-mouseIgG-APC BD Biosciences, Heidelberg 
Anti-mouseIgG-PE Dianova, Hamburg 
Anti-mouseIgG-HRP Rockland, Gilbertsville, PA, USA 
Anti-goatIgG-Cy3 BD Biosciences, Heidelberg 
Anti-goatIgG-Cy2 BD Biosciences, Heidelberg 
Anti-rabbitIgG-Cy3 BD Biosciences, Heidelberg 
Anti-rabbitIgG-Cy2 BD Biosciences, Heidelberg 
Anti-rabbitIgG-HRP Rockland, Gilbertsville, PA, USA 
Anti-GuineapigIgG-PE Dianova, Hamburg 
Anti-GuineapigIgG-biotin Rockland, Gilbertsville, PA, USA 
Streptavidin-PE Dianova, Hamburg 
Streptavidin-HRP Sigma, Steinheim 
Streptavidin-Cy3 Dianova, Hamburg 
Streptavidin-APC Dianova, Hamburg 
2.1.9 Expression vector 
All the chimeric constructs were cloned into pcDNA3.1(+) plasmid with hygromycin 
resistance.  
2.1.10 Bacterial strain 
E.coli DH5α       Genotype: F
-
, Φ80dlacZΔM15, Δ(lacZYA-argF)U169, 




), phoA, supE44, 
thi-1, gyrA96, rel A1, λ
-
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2.1.11 Cell lines 
BSp73AS (AS) a non-metastasizing rat pancreatic adenocarcinoma 
line     (Matzku et. al, 1983) 
BSp73ASML A highly metastatic rat pancreatic adenocarcinoma 
line Matzku et al., 1983 
AS-Tspan8 AS cells transfected with pcDNA3.1(+) neo 
containing Tspan8 cDNA (Claas et. al, 1998) 
AS-Tspan8/CD151c AS cells transfected with pcDNA3.1(+) Hygro 
containing Tspan8/CD151c cDNA 
AS-Tspan8/CD151n AS cells transfected with pcDNA3.1(+) Hygro 
containing Tspan8/CD151n cDNA 
AS-Tspan8/CD151c+n AS cells transfected with pcDNA3.1(+) Hygro 
containing Tspan8/CD151c+n cDNA 
AS-Tspan8/CD9c 
 
AS cells transfected with pcDNA3.1(+) Hygro 
containing Tspan8/CD9c cDNA 
AS-Tspan8/CD9n 
 
AS cells transfected with pcDNA3.1(+) Hygro 
containing Tspan8/CD9n cDNA 
AS-Tspan8/CD9c+n AS cells transfected with pcDNA3.1(+) Hygro 
containing Tspan8/CD9c+n cDNA 
AS-Tspan8-CD104 Herlevsen et al., 2003 
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Rat aorta endothelial cell line 
(RAEC) 
Isolated from Wistar rats, Cell lining, Berlin 
Fibroblasts (Fb) Isolated from lungs of BDX rats with NiSO4 
Stromal cells Isolated from lymph nodes of BDX rats 
2.1.12 Rat strain 
BDX rats were bred in animal facility of University of Heidelberg under pathogen-free 
conditions and were provided sterile food and water ad libitum. Rats in the age 9-11wk were 
used for experiments. 
2.2 Methods 
2.2.1 Molecular Biology   
2.2.1.1 Bacteria 
For all bacterial work DH5α was used. DH5α was cultured in liquid Luria Bertani (LB) 
medium or on solid LB-agar plates containing 60µg/ml ampicillin for selection. 
Transformations were carried out by either Eppendorf, Hamburg electroporator according to 
manufacturer‟s instructions, or by heat shock method as widely used. Briefly, 50µl of 
competent DH5α from -80˚C were kept on ice. 50ng of plasmid DNA was added and 
incubated for 10 min on ice. This bacteria-plasmid mix was placed at 42˚C for 45 seconds, 
and then placed back on ice for 2 min to reduce damage to bacteria. 1ml of LB was added 
and the bacteria incubated at 37˚C with agitation for 45min to 1hr. After this, around 100µl 
of the resulting culture were plated on an LB-agar selection plate and incubated 12-16h to get 
colonies.  
2.2.1.2 Plasmid-DNA- Preparation 
Plasmid miniprep and midiprep were done with Quiagen mini and midi-prep kits according 
to supplier‟s instructions. 
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2.2.1.3 Generation of chimeric constructs 
The following chimeric Tspan8 cDNA were generated: Tspan8/CD151c and Tspan8/CD9c 
with exchange of AA 198-235 by AA 214-253 of CD151 or AA 189-226 of CD9; 
Tspan8/CD151n and Tspan8/CD9n with exchange of AA 1-80 by AA 1-85 of CD151 or AA 
1-82 of CD9; CD151 and CD9, where the large extracellular loop (AA 86-205 of CD151 and 
AA 82-200 of CD9) were exchanged by AA 81-197 of Tspan8 (Tspan8/CD151c+n, 
Tspan8/CD9c+n). All construct were cloned into pcDNA3.1(+) using the restriction sites 
Kpnl and XhoI or Apa1 in a two step cloning procedure using the wt Tspan8, CD9 or CD151 
cDNA as templates and overlapping primers (TableA). After ligating the cDNA of chimeric 
molecules with the pcDNA3.1 (+) hygro, these plasmids were used for transforming E coli 
DH5α. which were grown on ampicillin containing LB-agar plates. Plasmids from bacterial 
colonies was digested as well as checked with PCR to verify correct insert-size. Promising 
plasmids were sent for sequencing to confirm the absence of any mutations.  Large quantities 
of the plasmid with chimeric cDNA insert were produced by plasmid midi-prep (Quiagen). 
 AS cells were stably transfected with these chimeric cDNA. Transfected AS clones were 
selected by growth in RPMI1640 supplemented with glutamine, antibiotics, 10% FCS and 
750µg/ml G418 under limiting dilution. Transfection with INS2-siRNA followed standard 
procedures as suggested by the supplier (Quiagen, Hildesheim, Germany). Efficiency of 
RNA silencing was monitored after 48h by WB. AS, transfected AS cells, aortic ring derived 
endothelial cell line (RAEC), Lung fibroblast and lymph node stroma lines  derived from rats 
were maintained in RPMI1640/ 10% FCS. Confluent cultures were detached by EDTA and 
split. 
Table 2.1 Scheme of PCRs for generating chimeric constructs 
Construct 1 PCR :Primers (Primer 
number as in table B) 
Template 2 PCR                     Template 
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Tspan8/CD151c Tspan8_CD151ec2_fw (3)  
CD151 cDNA 
Fragment PCR1  
Tspan8 
cDNA 
CD151_Apa1_rev (5) Tspan8_Kpn_fw (1) 
Tspan8/CD151n CD151_ Tspan8_fw (6)  
Tspan8cDNA 
Fragment PCR1  
CD151 
cDNA 
Tspan8_Xho1_rev (9) CD151_Kpn_fw (4) 
Tspan8/CD151c+n CD151/ Tspan8_fw (6)  
Tspan8/CD151c 
Fragment PCR1  
CD151 
cDNA 
CD151_Apa1_rev (5) CD151_Kpn_fw (4) 
Tspan8/CD9c Tspan8/ctCD9_fw (10)  
CD9 cDNA 
Fragment PCR1  
Tspan8cDNA CD9 XhoI_rev (11) Tspan8_KpnI-
Koz_fw (12) 
Tspan8/CD9n CD9 KpnI-Koz fw (7)  
CD9 cDNA 
Fragment PCR1  
Tspan8cDNA CD9/D6.1Aec2 rev (8) D6.1A_XhoI_rev (9) 
D6.1A/CD9n+c D6.1A/ctCD9_fw (10)  
CD9 cDNA 
Fragment PCR1  
D6.1A/CD9n CD9 XhoI_rev (11) CD9_Xho1_ rev (11) 
 
Table2.2 List of primers used for PCRs for generating chimeric constructs 
Primer Sequence in 5’-3’ orientation 








(7)CD9_ KpnI-Koz_fw 5‟-CAGGTACCGCCACC ATG GGCCGGTCAAAGGAG-3„ 
(8)CD9/D6.1Aec2_rv 5„ GAGAAGCATGCAGCGACTCTC TTGTACAGCTCCACAGCA-3‟ 
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(9)D6.1A XhoI_rv 5‟-GTCTCGAGTCATTTGCTTCCAATTTGG-3‟ 
(10)D6.1A/ctCD9_fw      5‟-ACAGAAAGAGACTATTTTTCGTTCAAGGTGTAGTAACCT- 3‟ 
(11)CD9 XhoI_rv 5‟-GTCTCGAGCTAGACCATTTCTCGGCTCCT-3‟ 
(12)D6.1A KpnI-Koz_fw 5‟-CAGGTACCGCCACCATGGCAGGTGTCAGTGGC-3‟ 
2.2.1.4 Dephosphorylation of plasmid DNA 
Recircularization of vector DNA was minimized by removing the 5´-phosphate residues from 
both termini of the linear, double-stranded plasmid DNA with calf intestinal alkaline 
phosphatase (CIAP, MBI Fermentas). The reaction was incubated at 37˚C for 30 min and 
then stopped by heating at 85°C for 15 minutes. 
2.2.1.5 Plasmid ligation 
 
For ligation of cDNA fragments into the plasmid T4 ligase with its lgation buffer (MBI 
Fermentas) was used. 200 ng of digested and dephosphorylated pcDNA3.1 (+) plasmid DNA 
were used. The amount of insert was calculated according to a molar ration 3:1 (insert: 
vector). The reactions were incubated for 1 hour at room temperature. To inactivate the 
Ligase the reaction was transferred to 70˚C for 15 min. To determine the efficiency of 
ligation, 5 µl of the reaction mix were run on an agarose gel and visualised with ethidium 
bromide. If the ligation was successful, 1-5 µl of the reaction mix was used for 
transformation of E.coli. 
2.2.1.6 siRNA transfection 
For the transfection of BSp73AS-Tspan8 cells, 5x10
4
 cells per well were plated in a 24-well 
plate. Next day, the cells were transfected with the INS2 siRNA (Quiagen, Hilden) according 
to manufacturer‟s protocol (HiPerfect-Reagent-Protocol, Quiagen, Hilden). The efficiency of 
transfection was checked by western blots 24, 48 and 72h after transfection. 
  
     Material and Methods                                                                                                                                                              36 
 
 
2.2.2 Cell biology 
2.2.2.1 Cell culture 
Eukaryotic cells were kept in RPMI 1640- medium, containing 10% heat inactivated fetal 
calf serum (FCS), 100U/ml penicillin, 100µg/ml streptomycin and maintained at 37˚C, 95% 
humidity and 5% CO2. For passaging, cells were detached with EDTA. 
2.2.2.2 Cryopreservation of eukaryotic cells 
1x10
7
 cells were harvested, washed once with fresh medium and resuspended in ice-cold 
FCS/10% DMSO. Cells were kept overnight at -80˚C and transferred to liquid nitrogen 
thereafter. 
2.2.2.3 Transfection of eukaryotic cells 
6x10
5 
AS cells were seeded the day before in a 6 well-plate. Next day, cells were transfected 
at ~80% confluency with Lipofectamine 2000 according to supplier‟s instructions.  
2.2.2.4 Recloning of transfected cells by limited dilution 
Transfected cells were selected for drug resistance and checked by FACs for expression of 
the transgene. Limited dilutions of 1 or 3 cells per well were carried out in a 96 well-plate. 
Cells were grown in the presence of 1x10
6
 freshly prepared rat thymocytes as feeder cells. 
Clones were checked by FACs and used for a second round of dilution to ensure a single cell 
clone. 
2.2.2.5 Adhesion assay 
Cells were CFSE-labeled (5µM) for 20min in serum free medium. After this, cells were 
washed twice in RPMI containing FCS and incubated for another 30min in fresh medium at 
37˚C. Following this, 5x10
4
 cells were seeded on BSA-, fibronectin (FN, 1µg/ml) - or 
laminin5 (Ln5, 2µg/ml) - coated plates or were seeded on a monolayer of RAEC. Where 
indicated, cells were PMA (10
-8
M) treated and/or the medium contained antibody (10µg/ml). 
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After 2h at 37˚C, plates were washed and adhesion was determined in Fluoroskan Ascent 
multiplate reader  (excitation: 490 nm, emission: 518 nm). 
2.2.2.6 Migration assays 
Subconfluent monolayers in a 6 well plate were scratched with a pipette tip. Wound healing 
was evaluated after 24h-72h by light microscopy. Transwell migration was evaluated using 
Boyden chambers with 8 m pore size membranes. Cells (1x106/ml, RPMI/0.1% FCS) were 
added to the upper chamber. Cells were stimulated by PMA (10-8M) or were pre-incubated 
with antibody (10µg/ml). RPMI1640/20% FCS was added to the lower chamber. After 12h 
incubation, migrated cells, on the lower surface of the filter were fixed with ice cold 
methanol and stained with crystal violet. Cells were dissolved in 10% acetic acid measuring 
absorbance at 595nm. 
2.2.2.7 Matrigel assay 
Matrigel was thawed overnight at 4˚C. The following day, it was diluted 1:1 with cold 
RPMI-1640 (serum free). 100µl of this dilution was plated carefully in wells of a 24- well 
plate. It was kept at 37˚C for 30min to solidify. Later, 5x10
4
 cells were seeded in 200µl 





 cells were grown on cover slips for 48hrs. Prior to staining, cells were fixed with 4% 
paraformaldehyde for 15min at RT, permeabilized with 0.2% tween in PBS-1%BSA, 
washed, blocked with 0.2% gelatin (freshwater goldfish) in PBS-1%BSA 15min and in-
cubated with primary antibodies (2-10µg/ml, 60min, 4˚C). Cover slides were rinsed and incu-
bated with a fluorochrome-conjugated secondary antibody (60min, 4˚C). After blocking, and 
incubation with a second, dye-labeled antibody (60min, 4˚C), cover slides were washed and 
mounted in elvanol.  
For internalization studies, cells were first incubated with a dye-labeled primary antibody or 
the primary antibody for 30min (4˚C), washed and incubated for the indicated time points 
     Material and Methods                                                                                                                                                              38 
 
 
with PMA 100nM at 37˚C for internalization. Following this, cells were immediately placed 
back on ice, fixed, permeabilized and thereafter incubated with secondary, dye-labeled anti-
body (60min, 4˚C).   
Where indicated, pre-starved cells (10h in serum free medium) were incubated with the dy-
namin inhibitor Dynasore (80µM in RPMI1640, 5h, 37˚C). After transfer on ice and blocking 
(PBS/0.5%BSA/0.2%gelatine), cells were incubated with the primary antibody, washed and 
incubated for 30min at 37˚C in the presence of PMA and Dynasore. Cells were washed, 
stripped, fixed, permeabilized and incubated with the dye-labeled secondary antibody and 
DAPI. Digitized images were generated using a Leica DMRBE microscope or a Carl Zeiss 
LSM710 confocal microscope and software Carl Zeiss Axioview Rel. 4.6. 
2.2.2.9 Flow cytometry 
1-3 10
5
 cells per sample were taken in a 96-well U bottom plate. Trypsinized cells were 
allowed to recover (2h, 37˚C, RPMI1640/10% FCS).  After washing with FACS buffer (PBS, 
1% FCS, pH7.4), cells were incubated with the primary antibody (1-5µg/ml) for 30min at 
4˚C, washed twice with FACS buffer and thereafter incubated with secondary, fluorochrome-
conjugated antibody (0.3-0.5µg/ml) for 30min, 4˚C. For double fluorescence, cells were 
incubated with a blocking antibody prior to incubations with the next set of primary and 
secondary antibody incubations. After 3 washes in FACS buffer, samples were acquired and 
analyzed with the FACS Calibur (BD, Heidelberg, Germany). Where mentioned, cells were 
fixed in 1% formalin (20min, 4˚C), washed and permeabilized with 0.2% tween In FACS 
buffer before incubations with the antibodies. 
For internalization studies, cells were stained with primary antibody on ice, washed and 
incubated at 37˚C for 30min. Afterwards, the cells were brought back to ice and the non-
internalized, surface bound antibody was stripped off, with PBS-HCl, pH2.5 (2washes, 5min, 
4˚C) Cells were then fixed and permeabilized followed by incubation with the secondary, dye 
labeled antibody (30min, 4˚C). Stripped samples were compared to non-stripped samples to 
quantify internalization. 
  
     Material and Methods                                                                                                                                                              39 
 
 
2.2.2.10 Exosome Isolation 
Supernatants from cells grown in serum free conditions were collected after 24-72h of 
culture, and processed through a density gradient centrifugation at 4˚C: 500g for 10min, 
2000g for 10min, 5000g for 20 min, 10,000g for 30min, followed by 2.5h of 
ultracentrifugation at 100,000g using SW41Ti rotor in Beckman Coulter ultracentrifuge. The 
exosome pellets were re-suspended in PBS, protein amount measured using Bradford assay 
and stored at -80˚C until use. 
2.2.2.11 Fluorescent-labeling of exosomes 
Exosomes were labeled directly or indirectly from cells. For indirect labeling, confluent cells 
in flasks were washed with PBS to remove all the FCS. Thereafter cells were labeled by 
incubation in medium (devoid of serum) containing either DHPE (Lissamine™ rhodamine B 
1, 2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine, triethylammonium salt. (rhodamine 
DHPE); excitation at 560 nm, emission at 586 nm) or SP-DioC18 (3) (excitation at 497nm, 
emission at 513nm) dyes diluted (1:10,000) for 30min in the incubator. After this, the cells 
were washed twice to get rid of excess of dye. Cells were then kept in culture for 48h without 
serum for later collecting exosomes. 
For direct labeling, 1mg of exosomes was labeled in 200µl of PBS containing DHPE or SP-
DioC18 (3) at 1:10,000 dilution in PBS for 15min RT. After this, the labeled exosomes were 
washed twice with exosome-depleted FCS so that the free dye binds to proteins in FCS. 
Exosomes were centrifuged down in between washes and after the last wash in PBS. The 
labeled exosome-pellet was then resuspended in PBS and stored at -80˚C till further use. 
2.2.2.12 FACS for evaluating exosomes subpopulations  
1µl Latex beads (4µm diameter) with activated aldehyde groups were pre-coated with D6.1 
or CD9 antibody (10µg/ml) overnight at 4˚C with agitation. Following this, the remaining 
free aldehyde groups were quenched by incubation with PBS-100mM Glycine for 30min, 
RT. Then, 20µg of DHPE labeled exosomes were incubated with the pre-coated beads for 
2hr at RT. The bead-unbound exosomes were collected and bound to uncoated beads. After 
washing with PBS-1% FCS (exosome depleted), the exosome-bead complex was incubated 
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with primary antibody (5µg/ml) for 30min, RT, washed, and incubated with the APC-
conjugated secondary antibody (0.3µg/ml) for 30min, RT. After washing, samples were 
acquired and analyzed with FACS Calibur. 
2.2.3 Animal experiments 
2.2.3.1 In vivo exosome targeting 
SP-DioC18 (3) (Invitrogen, Darmstadt) labeled 250µg exosomes were injected intravenously 
(i.v.) in the tails of BDX rats (9-11wk). After 24h, the rats were sacrificed, organs extracted, 
and meshed through cotton gauze to prepare cell suspensions for FACS analysis. Parts of 
organs were also frozen in liquid nitrogen in Neg-50 embedding medium for later analysis 
with confocal microscopy. 
2.2.3.2 Ex vivo exosome binding  
Organs from healthy BDX rats were extracted and the cell suspensions from various organs 
were co-incubated with 20µg/ml of DHPE-labeled exosomes for 6h. Cells were then 
distributed in U-form 96well plates for FACS. Cells were washed, fixed and permeabilized 
prior to incubation with primary antibody (30min, 4˚C), washed and incubated with the APC- 
conjugated secondary antibody (30min, 4˚C). 
2.2.3.3 Cell and tissue preparation 
Heparinized peripheral blood was collected by heart puncture. Peripheral blood mononuclear 
cells (PBL) were collected after Ficoll-Hypaque gradient centrifugation. Peritoneal exudate 
cells (PEC) were collected by flushing the peritoneal cavity with 10ml PBS/heparin. Bone 
marrow cells (BMC) were collected from femur and tibia by flushing the bones with 5ml 
PBS. Spleen and LN cells (SC, LNC) were obtained by pressing the organs through fine 
gauze. Liver, lung, pancreatic and submandibular gland cells were collected from minced 
tissue after 3x30min treatment with a collagenase, dispase mix. Alternatively, solid organs 
were shock frozen in liquid nitrogen. 
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2.2.3.4 Statistical analysis 
All assays, which were statistically evaluated, were repeated at least 3 times. P-values <0.05 
(two tailed Student‟s t-test and Anova) were considered significant. 
2.2.4 Protein Biochemistry 
2.2.4.1 Biotinylation 
Cells were washed in cold HEPES buffer and, incubated with 0.1mg/ml water-soluble 
Biotin-X-NHS in HEPES buffer on a shaking platform (30min, 4°C). Cells were washed with 
PBS-200mM Glycine and lysed (HEPES buffer, 1% Lubrol or 1% Brij96, 1mM PMSF and 
protease inhibitor cocktail) for 60min, 4°C.  Exosomes were biotinylated similarly, after 
quenching and washing, ultracentrifugation steps (100,000g for 2,5h) were required to pellet 
down the exosomes. 
2.2.4.2 Immunoprecipitation (IP) 
Lysates from cells were centrifuged for 15min at 15000g to remove unsolubilized material 
and cell nuclei. 1mg for cell lysates or 100µg exosomal lysate was immunoprecipitated with 
corresponding antibody (2µg/mg of lysates or 200µl hybridoma) O/N at 4°C, followed by 
incubation with 5% proteinG-Sepharose (1h) with rotation. Thereafter, the complexes were 
washed four times with lysis buffer. After the last wash, all the liquid was removed through a 
35g-needle attached to a vacuum pump to ensure minimal background. Complexes were 
resuspended in Laemmli buffer and boiled for 5min at 95˚C. Sepharose beads were separated 
by a quick spin at 15000g for 15sec and the supernatant was subjected to SDS-PAGE. 
2.2.4.3 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
For electrophoretic separation of protein samples the „Mini-Protean II‟ system was used for 
discontinuous SDS-PAGE. 5ml of separating gel (375mM Tris pH8.8, 0.1%SDS, 10-12% 
acrylamide-bisacrylamide, 0.1%TEMED (v/v), 0.1% (w/v) ammonium persulphate) was 
overlaid with 2ml of stacking gel (375mM Tris pH6.8, 0.1%SDS, 4% acrylamide-
bisacrylamide, 0.1%TEMED (v/v), 0.1% (w/v) ammonium persulphate). After complete 
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polymerization, gels were loaded and run in gel running buffer at a constant voltage of 120V. 
Gels were either silver stained or subjected to western blot analysis. 
2.2.4.4 Western blotting  
After SDS-PAGE, protein gels were equilibrated for 10min in transfer buffer. Nitrocellulose 
membranes (Amersham, Freiburg) and 3MM Whatman paper were equilibrated as well. For 
protein transfer, the gel was placed on Whatman paper, followed by nitrocellulose and 
another layer of Whatman paper. The wet transfer was carried out in transfer buffer at a 
constant voltage of 30V O/N at 4˚C. 
After transfer had been completed, the membranes were blocked for 1h at RT with 5% (w/v) 
fat-free milk in PBST (PBS, 0.1% (v/v) Tween-20). Antibody incubations were carried out 
for 1h at RT with hybridoma supernatant or purified antibody in PBST-milk. Membranes 
were then washed three times, 5min each in PBST and then probed with horse radish 
peroxidase (HRP)-conjugated secondary antibody (diluted 1:10000 in PBST) for 1h at RT, 
followed by additional three washing steps. Biotinylated proteins were detected with 
Streptavidin-peroxidase. Detection was done by chemiluminiscence using the „ECL Western 
blotting detection reagents‟ and „ECL radiography films‟ from Amersham, Freiburg. 
2.2.4.5 Silver staining of protein gels 
After separation of proteins by SDS-PAGE, gels were fixed overnight in 30% ethanol/ 10% 
acetic acid and sensitized for 45min in 0.3% potassium tetrathionate, 0.5M potassium 
acetate, 30% ethanol. This was followed by 6 washes, totally for 1h with bidest water. Gels 
were stained with 0.2% silver nitrate for 1-2h, rinsed with bidest water and developed for 
upto 40min in developer (3% potassium carbonate, 31µl Na2S2O3-5H2O (10%), 75µl 
formalin (37%) per 250ml). The reaction was stopped by adding 330mM Tris/ 2% acetic acid 
and gels were kept in bidest water. 
2.2.4.6 Sucrose Gradient Ultracentrifugation 
800µl of cell lysates were mixed with 800µl of 80% sucrose (prepared in 1x HEPES) 
yielding 1.6ml lysates in 40% sucrose which was placed at the bottom of a 4ml 
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ultracentrifuge tube. Over this was laid, 1.6ml of 30% sucrose in HEPES followed by a layer 
of 5%sucrose in HEPES on the top. The tubes were carefully placed in a SW41Ti rotor and 
centrifuged in an ultracentrifuge (Beckman Coulter, Krefeld) at 30000 rpm/100,000g at 4 ˚C 
for 13h. Afterwards, 12 equal fractions were collected from each tube and either used for 
SDS PAGE directly, or used for IPs after pooling several fractions and their dialysis. 
 
                        
 




It was recently described in our lab, that a tumor cell line overexpressing the tetraspanin 
Tspan8 delivers exosomes that induce resting endothelial cell (EC) activation and angio-
genesis (Gesierich et al., 2006). Notably, AS-Tspan8 cells express besides Tspan8, the 
tetraspanins CD9, CD81, CD151 at comparable levels, which are also expressed on 
exosomes derived from AS, AS-Tspan8-CD104. But, only AS-Tspan8 exosomes promoted 
angiogenesis in vivo and not AS or the AS-Tspan8-CD104 derived exosomes. This selective 
activity of exosomal Tspan8 and Tspan8-associated CD49d prompted us to explore the 
feature of Tspan8 internalization.  
3.1 Tspan8, CD9 and CD151 get internalized differently  
Exosome delivery is known to be strengthened under stress conditions (Parolini et. al, 2009). 
Keeping this in mind, and also to avoid selective endocytosis of individual tetraspanins 
which can be triggered by antibody cross-linking, we evaluated internalization in PMA-
treated cells. AS and AS-Tspan8 cells were incubated with D6.1 (anti-Tspan8), anti-CD9 or 





C, 5%CO2. Thereafter, cells were fixed, permeabilized and stained with the 
secondary antibody. CD151 becomes internalized within 10-30min of PMA-treatment 
whereas, Tspan8 internalization requires 30min with complete internalization seen after 
60min. CD9 remains at the plasma membrane until 30min of PMA-treatment and is partially 
internalized after 60min (Fig. 1A).  
To confirm the process of tetraspanin internalization, recovery of surface-bound antibody 
was measured by flow cytometry after internalization for 30min and stripping in non-perme-
abilized versus permeabilized PMA-treated AS-Tspan8 cells. Surface staining of Tspan8, 
CD9 and CD151 was largely lost after stripping. However, Tspan8 and CD151, but not CD9, 
were recovered in PMA-treated, stripped and permeabilized AS-Tspan8 cells. This confirmed 
internalization of CD151, partial internalization of Tspan8 and persisting membrane 
expression of CD9 (Fig.1B). These findings also pointed towards Tspan8 internalization pro-
ceeding independent of the tetraspanin web. To further support this hypothesis, AS-Tspan8 
and ASML cells were PMA-treated and thereafter stained with D6.1-TxR and anti-CD9-
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FITC. Indeed, Tspan8 co-localizes with CD9 in untreated, but not in PMA-treated AS-
Tspan8 cells (Fig.1C). The same finding accounted for co-localization of Tspan8 with 
CD151, however, co-localization in untreated cells was weaker than co-localization of 
Tspan8 with CD9 (Fig.1D). The rapid internalization of Tspan8 was unexpected, because 
Tspan8 does not contain a properly located internalization motif. We therefore generated 
Tspan8 chimeric molecules to explore, which region of Tspan8 accounts for the more rapid 
internalization compared to CD9.  
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Figure 1. PMA-induced internalization of CD9, CD151 and Tspan8: (A) AS and AS-Tspan8 cells were 
incubated at 4
o
C with anti-CD9, anti-CD151, D6.1 (anti-Tspan8), washed, treated for 10, 30 or 60min with 
PMA (37
o
C) and stained with the secondary dye-labeled antibody. The tetraspanin distribution was evaluated 
by confocal microscopy, including sagittal sections (scale bar: 10µm). (B) AS-Tspan8 cells, stained with 
D6.1, anti-CD9 and anti-CD151, were treated for 30min with PMA. Surface and permeabilized staining are 
shown. Where indicated, cells were permeabilized or first the membrane bound staining was stripped and then 
cells permeabilized to reveal internalization. Overlays with the negative control and the mean percentage of 
stained cells are presented. (C and D) Co-localization of Tspan8 with CD9 (C) and CD151 (D) during PMA-
treatment of AS-Tspan8 and ASML cells was evaluated by fluorescence microscopy after staining with D6.1-
TxR and CD9-FITC or CD151-FITC. Single fluorescence staining and overlays are shown (scale bar: 10µm).            
3.2 PMA induced internalization of chimera vs. Tspan8 
Six chimeric constructs were created as follows: Tspan8/ CD151n, Tspan8/CD9n where the n 
terminus of Tspan8 was exchanged with amino acids of CD9 or CD151 n-terminus. Tspan8/ 
CD151c, or Tspan8/CD9c where the c-terminus of Tspan8 was exchanged for c-terminus of 
CD9 or that of CD151 and; Tspan8/CD151n+c, Tspan8/CD9n+c  where both the c- and n- 
termini were exchanged with either those of CD9 or CD151.  The cDNA of these constructs 
were cloned into pcDNA3.1 (+) vector which also contained hygromycin resistance cassette. 

















































Table 1. Protein sequences of Tspan8, CD151, CD9 and the chimeric constructs. Blue: transmembrane 
regions; red: extracellular regions; black: intracellular regions; Large italic font: exchanged regions 
AS cells were transfected with pcDNA3.1 (+) containing cDNA of Tspan8 or the Tspan8 
chimeric constructs using Lipofectamine 2000. Limited dilution to get single stable clones 
was carried out under selection pressure. Expression levels were checked by FACS. A 
schematic presentation of the constructs is shown in Fig2A and expression of the chimeric 
Tspan8 molecules is shown in Fig2B. Tspan8 and the chimeric constructs were expressed at 
comparable levels in the AS cells, and thus could be used in further experiments for 
comparisons. We first evaluated whether these chimera may become internalized with 
different kinetics.  
 
Figure.2.Chimeric constructs and their expression (A) Schematic representation of chimeric constructs. (B) 
Surface expression of the chimeric constructs in AS cells. Cells were stained with D6.1 (30min, 4˚C), washed 
with PBS and incubated with PE conjugated secondary Ab, washed and measured with FACS Calibur. 
As revealed by D6.1-TxR staining, PMA-treatment and permeabilization, exchange of the N-
terminal region particularly by that of CD9 was accompanied by retarded Tspan8 
internalization (Fig.3A). The latter has been confirmed by flow cytometry, where after 
stripping hardly any intracellular Tspan8/CD9n was recovered, whereas internalization of 
Tspan8/CD151c was unimpaired (Fig.3B).  
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Evaluating co-localization of Tspan8 with CD9 after PMA-treatment confirmed exchange by 
the CD9 N-terminal and, less pronounced, the CD151-N-terminal region to promote 
persisting membrane expression of Tspan8 and co-localization of Tspan8 with CD9 in the 
plasma membrane. Instead, exchange of the Tspan8 C-terminal region by that of CD9 or 
CD151 had no effect on Tspan8 internalization and Tspan8 did not co-localize with CD9 
after PMA-treatment (Fig.3C). The weaker co-localization of Tspan8 with CD151 was 
affected to a lesser extent by exchange of the Tspan8 C- or N-terminal region (data not 
shown). However, it should be mentioned that the CD151 C-terminal region, which contains 
a YxxΦ internalization motif, did not suffice to stabilize co-internalization of Tspan8 and 
CD151, which excludes a major contribution of the YxxΦ internalization motif of CD151 in 
Tspan8 internalization. 








Figure 3. Internalization of chimeric molecules, and colocalization with CD9. (A) Time course of PMA-induced 
Tspan8-chimeric molecule internalization. Tspan8 localization was evaluated by fluorescence microscopy at 0-60 min of 
PMA-treatment (scale bar: 10µm). (B) Cells incubated with D6.1 (4
o
C) and treated, where indicated, with PMA for 0min 
or 30min (37
o
C); Cells were stripped where indicated, fixed, permeabilized and counterstained with anti-mIgG-PE. 
Overlays with the negative control and the mean percentage of stained cells are presented.  (C) Co-localization of Tspan8 
with CD9 in untreated and PMA- treated AS-Tspan8-chimeras was evaluated by confocal microscopy. Overlays of 
Tspan8-Cy2 and CD9-TxR staining are shown (scale bar: 10µm). 
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3.3    The route of internalization 
3.3.1 Vesicular trafficking 
Internalized membrane microdomains are recruited into early endosomes from where they 
can proceed to late endosomes. Alternatively, via ubiquitinylation and fusion with lysosomes 
proteins may become degraded. Early endosomes also can incorporate into MVB, migrate 
towards and fuse with the cell membrane such that the invaginated early endosomes are 
released as exosomes (de Gassart et al., 2004, Denzer et al., 2000, Stahl et al., 2002, van Niel 
et al., 2006). After PMA-treatment, Tspan8, distinct from CD9, mainly co-localized with the 
early endosomal marker Rab5, and rarely with the late endosomal marker Rab7. Tspan8 and 
CD9 also co-localized with LAMP1, which is found in late endosomes and synthetic 
pathway vesicles (Chapuy et al., 2008, Lakkaraju et al., 2008) (Fig.4A). Co-localization of 
Tspan8 with rab7 and Lamp1 was not significantly altered in AS cells expressing Tspan8 
chimeric molecules. However, Tspan8/CD9n poorly and Tspan8/CD9c+n hardly co-localized 
with Rab5 (Fig.4B).          
Taken together, PMA-treatment promotes Tspan8 internalization more efficiently than that of 
CD9 and co-localization of Tspan8 with CD9 and CD151 is not maintained. Also distinct 
from CD9, Tspan8 is mostly recovered in early endosomes. The analysis of Tspan8 chimeric 
molecules so far indicated that the Tspan8 N-terminal region might contribute to Tspan8 
internalization. This led to addressing the question whether Tspan8 becomes internalized via 
molecules that selectively associate with Tspan8. 
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Figure 4: Vesicular traffic of Tspan8 in PMA-treated cells: (A) AS and AS-Tspan8 were PMA-treated (37˚C), 
fixed and permeabilized and stained with anti-CD9 or anti-Tspan8, the secondary dye-labeled antibody and anti-Rab5, 
anti-Rab7 and anti-Lamp1. (B) AS-Tspan8 and AS-Tspan8-chimeric cells were incubated with D6.1 (4˚C), PMA-
treated (37˚C), fixed and permeabilized and stained with the secondary dye-labeled antibody and anti-Rab5, anti-Rab7 
and anti-Lamp1. Merged views of fluorescence (A) or confocal (B) microscopy are shown (scale bar: 10µm). 
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3.3.2   Involvement of Intersectin-2 
Tspan8 directly associates with EWI-F, the dipeptidase CD13 and INS2 (Claas et al., 2005, 
Le Naour et al., 2006, Claas et al, in prep.). These three molecules co-immunoprecipitate 
with Tspan8 after lysis in Brij96 and co-immunoprecipitation is maintained after PMA-
treatment. A similar immunoprecipitation profile is seen with CD151, although the co-
immunoprecipitation with INS2 becomes weaker after PMA-treatment. Instead, CD9 mostly 
co-immunoprecipitates with EWI-F. It also should be noted that Tspan8, though weakly co-
localizing, co-immunoprecipitates with CD151 in untreated and PMA-treated AS-
Tspan8cells, whereas co-immunoprecipitation of Tspan8 with CD9 becomes weak in PMA  
 




Figure 5. Tspan8 associates and co-internalizes with INS2: (A) Lysates of AS-Tspan8 cells were immunoprecipitated 
with D6.1, anti-EWI-F, anti-INS2 and anti-CD13. After SDS-PAGE separation and protein transfer, membranes were 
blotted with D6.1, anti-CD9 and anti-CD151. (B) AS-Tspan8 cells were PMA-treated and co-localization of Tspan8, 
CD9 and CD151 with EWI-F and INS2 was evaluated by fluorescence microscopy (scale bar: 10µm). Overlays of single 
fluorescence staining are shown. (C) Co-internalization of Tspan8 and CD9 with EWI-F and INS2 in PMA-treated AS-
Tspan8-chimeras was evaluated by confocal microscopy (scale bar: 10µm).. Overlays of Tspan8 and CD9 staining with 
EWI-F and INS2 are shown. (D) Lysates of untreated and PMA-treated AS-Tspan8-chimeras were immunoprecipitated 
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with D6.1 or anti-INS2. Precipitates were separated by SDS-PAGE. After transfer, blots were developed with anti-
CD151, anti-EWI-F and anti-INS2 or D6.1. 
treated AS-Tspan8 cells (Fig.5A). Fluorescence microscopy confirmed co-localization of 
Tspan8, CD9 and CD151 with EWI-F. Co-localization of Tspan8, CD9 and, weakly, CD151 
with EWI-F is maintained after PMA-treatment. The stronger co-localization of Tspan8 and 
the weaker one of CD151 with INS2 are maintained in PMA-treated AS-Tspan8 cells. 
Instead, weak co-localization of CD9 with INS2 is further reduced (Fig.5B). Co-localization 
of Tspan8 and CD9 with EWI-F during internalization is maintained in Tspan8-chimeras. 
This also accounts for the weak co-localization of CD9 with INS2. On the contrary, strong 
co-localization of Tspan8 with INS2 becomes weak in PMA-treated AS-Tspan8/CD9n 
chimeras (Fig.5C). All Tspan8 chimeric molecules weakly co-immunoprecipitate with 
CD151 and, though to a variable degree, with EWI-F. They also co-immunoprecipitate with 
INS2. However, after PMA-treatment, co-immunoprecipitation of INS2 with Tspan8 
chimeras becomes weak and is no longer seen in AS-Tspan/CD9n and AS-Tspan8/CD9c+n 
chimeras. This was confirmed in the reverse setting, where INS2-immunoprecipitate of 
untreated cells contains little Tspan8/CD9n and Tspan8/CD9c+n. After PMA-treatment INS2 
does not co-immunoprecipitate Tspan8/CD9n and Tspan8/CD9c+n, although comparable 
amounts of Tspan8 are precipitated by D6.1, which confirms reduced association of 
Tspan8/CD9n and Tspan8/CD9c+n with INS2 after PMA-treatment (Fig.5D). 
INS2 being involved in clathrin-mediated endocytosis (Simpson et al., 1999), we next asked 
whether Tspan8, CD151 and CD9 are co-localizing or co-immunoprecipitating with clathrin 
and, for comparison, with caveolin. In untreated AS and AS-Tspan8 cells, the three tet-
raspanins strongly co-localize with clathrin, but co-localization of CD9 with clathrin 
becomes weak after PMA-treatment. Instead, co-localization of CD9 with caveolin is 
stronger after PMA-treatment (Fig.6A). Tspan8 does not or rarely co-localize with caveolin 
in PMA-treated AS-Tspan8 and AS-Tspan8-chimeras, but co-localizes with clathrin, except 
in AS-Tspan8/CD9n and AS-Tspan8/CD9c+n cells, where weak co-localization is mostly 
restricted to the cell membrane (Fig.6B). Co-immunoprecipitation confirmed that Tspan8 
preferentially co-immunoprecipitates with clathrin. Instead, CD9 and CD151 co-immunopre-
cipitate with both clathrin and caveolin (Fig.6C). Anti-clathrin also immunoprecipitated 
chimeric Tspan8. However, co-immunoprecipitation became weak in PMA-treated AS-
Tspan8/C9, particularly, AS-Tspan8/CD9c+n chimeras (Fig.6D). These data argued for the 
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N-terminal region of Tspan8 being essential for internalization as well as for a contribution 
of INS2 and clathrin.  
 
Figure 6. Tspan8 co-localizes and co-internalizes with clathrin: (A and B) Untreated and PMA-treated AS, AS-Tspan8 and 
AS-Tspan8 chimeras were incubated with anti-CD9, anti-CD151 or D6.1 and were fixed after incubation with / without PMA at 
37
o
C, permeabilized and stained with the secondary dye-labeled antibody and anti-caveolin or anti-clathrin. Overlays of confo-
cal microscopy are shown (scale bar: 10µm).). (C) Lysates of untreated and PMA-treated AS-Tspan8 cells were 
immunoprecipitated with anti-caveolin or anti-clathrin. Precipitates were separated by SDS-PAGE and after transfer blotted 
with D6.1, anti-CD9 and anti-CD151. (D) Lysates of untreated and PMA-treated AS-Tspan8 and AS-Tspan8 chimera were 
immunoprecipitated with anti-clathrin. Precipitates were separated by SDS-PAGE and after transfer blotted with D6.1. 
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Clathrin-mediated endocytosis requires dynamin, which co-operates with INS2 (Yamabhai et 
al., 1998). To confirm the involvement of clathrin and INS2 in Tspan8 internalization, AS-
Tspan8 cells were PMA-treated in the presence of the dynamin inhibitor Dynasore. Inter-
nalization was evaluated by confocal microscopy after stripping surface bound antibody by 
an acid wash. Internalization of Tspan8, CD151 and TfR, which served as positive control, 
but not the weak internalization of CD9, was strongly inhibited in the presence of Dynasore 
(Fig. 7A, B).  
Figure 7. Tspan8-INS2 complex internalization requires dynamin: (A and B) AS-Tspan8 cells were cultured in the 
presence or absence of Dynasore (80µM) for 5h. Cells were incubated with D6.1, anti-CD9 or anti-CD151 at 4
o
C, incubated 
with PMA (30min, 37
o
C) and transferred on ice. Surface-bound antibody was removed by acid wash (PBS/HCl, pH2.5). Cells 
were fixed, permeabilized, stained with the secondary dye-labeled antibody and counterstained with DAPI. Internalized 
Tspan8, CD9 and CD151 were evaluated by confocal microscopy (scale bar: 10µm).). (A) Representative examples. (B) 
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mean± SD of fluorescence intensity of 10 microscopic fields (corresponding field size as shown in A). Significant inhibition of 
internalization by Dynasore is indicated by *.                          
To reinsure the essential contribution of INS2, AS-Tspan8 cells were treated with INS2 
siRNA (Fig.8A). When AS-Tspan8-INS2
kd
 cells were stained with D6.1 and thereafter PMA-
treated, Tspan8 internalization was strongly reduced, whereas CD151 and weak CD9 
internalization was hardly affected (Fig.8B and 8C). Furthermore, co-immunoprecipitation of 
Tspan8 and dynamin with clathrin was strongly reduced in untreated and was abolished in 
PMA-treated AS-Tspan8-INS2
kd
 cells (Fig.8D). 
Co-localization of Tspan8 with clathrin is in line with the preferential internalization of some 
tetraspanins via clathrin-coated pits (Helle et al., 2008, Pols et al., 2009, Xu et al., 2009) as 
well as the direct association of Tspan8 with INS2 (Claas et al., 2005, Claas et al, in 
prep.).However, there remained the question, why the association of Tspan8 with clathrin 
and INS2 became strengthened by PMA-treatment, whereas the association with CD9 
became weaker. The finding suggests that Tspan8 becomes recruited into membrane domains 
distinct from TEM (tetraspanin-enriched microdomain) in the resting cell. 
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Figure 8. INS2 is a key player in dynamin dependent Tspan8 internalization (A-D) AS-Tspan8 cells were treated with 
INS2 siRNA. (A) WB of mock- and siRNA-treated AS-Tspan8 cells with D6.1, anti-INS2 and anti-actin. (B and C) AS-
Tspan8 and AS-Tspan8-INS2
kd
 cells were incubated with D6.1, anti-CD9 and anti-CD151, incubated with PMA, fixed, 
permeabilized and stained with the dye-labeled secondary antibody. Internalization was evaluated by confocal microscopy 
(scale bar: 10µm). (B) Representative examples; (C) Mean± SD of fluorescence intensity of 10 microscopic fields 
(corresponding field size as shown in D). Significant inhibition of internalization by INS2-siRNA is indicated by *. (D) 
Lysates of AS-Tspan8 and AS-Tspan8-INS2
kd
 cells were precipitated with anti-clathrin. Precipitates were separated by SDS-
PAGE and after transfer blotted with D6.1 and anti-dynamin. 
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3.4 Changes in Tspan8 partners during internalization 
To support the hypothesis of a rearrangement of the Tspan8 web by PMA-treatment, the 
distribution of Tspan8, CD151 and CD9 in membrane microdomains was evaluated by 
sucrose density gradient centrifugation. In untreated cells, Tspan8, CD151 and CD9 were 
enriched in the density fraction of d1.117-d1.130. When cells were treated with MßCD, the 
tetraspanins shifted towards heavier fractions. After PMA-treatment, Tspan8 and CD151, but 
not CD9 were enriched in lighter fractions (d1.112-d1.122). Notably, Tspan8 remained in the 
lighter fractions after MßCD treatment (Fig.9A). Importantly, after PMA-treatment, Tspan8, 
INS2 and clathrin co-immunoprecipitated in the light fraction of density 1.112 (Fig.9B). 
 
Figure 9. PMA-induced membrane sub-domain redistribution of Tspan8: (A) Untreated and PMA-treated AS-
Tspan8 cells were incubated with MβCD for partial cholesterol depletion. Cells were lysed and lysates subjected to 
sucrose density gradient centrifugation. Fractions were SDS-PAGE separated, transferred and blotted with D6.1, anti-
CD9, and anti-CD151. (B) Untreated and PMA-treated AS-Tspan8 cells were lysed and lysates were subjected to sucrose 
density gradient centrifugation. Fraction 1, 2, 3, 4 and pooled fractions 5-8 and 9-12 were immunoprecipitated with D6.1 
or anti-clathrin. Precipitates were separated by SDS-PAGE. Proteins were transferred and membranes were blotted with 
D6.1, anti-INS2 and anti-clathrin. 
Recovery of the Tspan8-INS2-clathrin complex after PMA-treatment in lighter density 
fractions supported the hypothesis of a PMA-induced reorganization of Tspan8 complexes, 
and thus encouraged to search for additional partners that might contribute to reorganization 
of Tspan8-containing membrane micro-domain. The associations of Tspan8 with integrins 
vary depending on the integrin profile of the cell. Thus, as shown by previous lab members 
in another system: in ASML cells, Tspan8 is associated with CD49c and CD104/CD49f 
(Claas et al., 1998, Herlevsen et al., 2003), the association with CD104 becoming dominant 
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in PMA-treated cells (Herlevsen et al., 2003, Gesierich et al., 2005). In AS-Tspan8 cells, 
Tspan8 mostly is associated with CD49c, and weakly with CD49d. After PMA-treatment the 
association with CD49c becomes weak and is restricted to the cell membrane, whereas 
cytoplasmic Tspan8 strongly associates with CD49d. This also accounts for co-
immunoprecipitation. Only after PMA-treatment, CD49d is recovered in the light density 
fractions, where it co-immunoprecipitates with Tspan8. On the other hand, co-immunopre-
cipitation of CD49c with Tspan8 becomes weaker and is mostly restricted to the heavier 
density fractions (Fig.10A, 10B). 
Exchange of the CD151 or CD9 C-terminal region does not affect the association of Tspan8 
with CD49d during PMA-induced internalization. On the contrary, exchange with the CD151 
and, far more pronounced, the CD9 N-terminal region interferes with the co-localization of 
Tspan8 and CD49d (Fig.10C). Co-immunoprecipitation of CD49c and CD49d with Tspan8 
chimeras confirms that the association with CD49d becomes strengthened by PMA-
treatment, but is significantly weakened, when the N-terminal region of Tspan8 is exchanged 
by that of CD9. In contrast, CD49c readily co-immunoprecipitated with Tspan8/CD9n and 
CD9c+n after PMA-treatment (Fig.10D). 
As CD49d associates with Tspan8 during PMA-treatment / internalization and co-
immunoprecipitates with Tspan8 mostly in the light density fractions, CD49d could be a 
potential candidate for the recruitment of Tspan8 towards INS2 and clathrin. Obviously, 
CD49d remains Tspan8-associated during the vesicular transport, as CD49d co-
immunoprecipitates with Tspan8 in exosomes which we also have shown before (Nazarenko 
et al., 2010). 
If our hypothesis is correct that Tspan8 by its association with INS2 and the recruitment of 
CD49d becomes enriched in MVB such that the complex is exocytosed rather than degraded 
or reintegrated in the plasma membrane, PMA stimulation of AS-Tspan8 cells should be 
accompanied by reduced matrix and cell adhesion. 
 
 









Figure 10. During PMA-induced internalization, Tspan8 associates with CD49d: (A) Untreated and PMA-treated AS 
and AS-Tspan8 cells were stained with anti-CD9 or D6.1 and anti-CD49c or anti-CD49d. Overlays of confocal mi-
croscopy are shown (scale bar: 10µm). (B) Sucrose density gradient fractions of lysates of untreated and PMA-treated 
AS-Tpan8 cells were blotted with D6.1 and anti-CD49d or were precipitated with D6.1. Precipitates were separated by 
SDS-PAGE and after transfer blotted with D6.1, anti-CD49c and anti-CD49d. (C) PMA-treated AS-Tspan8 chimeras 
were stained with D6.1 and anti-CD49c or anti-CD49d. Overlays of confocal microscopy are shown (scale bar: 10µm). 
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(D) Lysates of untreated and PMA-treated AS-Tspan8 and AS-Tspan8 chimera were immunoprecipitated with anti-
CD49c or -CD49d. Precipitates were separated by SDS-PAGE and after transfer blotted with D6.1. 
3.5 Adhesiveness and motility of PMA-stimulated AS-Tspan8 cells 
Matrix adhesion, cell-cell adhesion and migration have been evaluated with AS, AS-Tspan8 
and all AS-Tspan-chimeras. As the most striking differences were observed upon exchange 
of the Tspan8 N-terminal region by that of CD9, only the impact on functional activity of the 
latter chimera in comparison to AS and AS-Tspan8 cells will be presented. 
Unstimulated AS and AS-Tspan8 cells readily adhere to FN and Ln5, but poorly to BSA. 
PMA stimulation decreased adhesiveness of AS-Tspan8 to FN and Ln5, but adhesion of AS-
Tspan8/CD9n cells was not affected (Fig.11A). D6.1 significantly inhibited Ln5 adhesion of 
AS-Tspan8. PMA-treatment strongly reduced inhibition by D6.1. Instead, weak inhibition of 
AS-Tspan8/CD9n was not affected by PMA-treatment. The very same feature of inhibition 
was seen with anti-CD49d. Instead, anti-CD49c equally well inhibited untreated and PMA-
treated AS-Tspan8 cells and more efficiently inhibited adhesion of PMA-treated than 
untreated AS- Tspan8/CD9n cells (Fig.11B). From there, we conclude that Tspan8 con-
tributes to matrix adhesion only in the resting state, where Tspan8 is preferentially associated 
with CD49c. 
We observed recently that the AS-Tspan8 cells adhered more readily to RAEC than AS cells 
(Nazarenko et al., 2010). Adhesion to RAEC was strongly reduced in AS-Tspan/CD9n cells. 
PMA-treatment only reduced adhesion of AS-Tspan8 cells (Fig.11C). Similar to matrix 
adhesion, D6.1 and anti-CD49d inhibited RAEC binding significantly less efficiently when 
AS-Tspan8 cells were PMA-treated. 
The weaker inhibition of AS-Tspan8 binding to RAEC by anti-CD49c was not affected by 
PMA-treatment. Weak inhibition of AS-Tspan8/CD9n binding to RAEC by D6.1, anti-
CD49d and anti-CD49c was not affected by PMA-treatment (Fig.11D). Different from 
adhesion, PMA-treatment strengthened migration. Wound closure of AS-Tspan8 cells 
proceeded faster than that of AS cells and AS-Tspan8/CD9n cells and was further accelerated 
in the presence of PMA. 
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Figure 11. Impact of the N-terminal regions of Tspan8 on matrix and cell adhesion: (A) Adhesion to Ln5 and FN of 
untreated and PMA-treated AS, AS-Tspan8 and AS-Tspan8/CD9n cells. The percentage of adherent cells was evaluated 
after 2h incubation at 37
o
C. (B) Untreated and PMA-treated cells as in (A) were seeded on Ln5 in the presence of D6.1, 
anti-CD49c and anti-CD49d. The percent inhibition as compared to (A) is shown. (C and D) CFSE-labeled untreated and 
PMA-treated AS, AS-Tspan8 and AS-Tspan8/CD9n cells were seeded on a monolayer of RAEC and incubated for 2h. 
The percentage of adherent cells is shown. (D) Adhesion to RAEC was evaluated in the presence of D6.1, anti-CD49c or 
anti-CD49d. The percent inhibition as compared to cells incubated in the presence of control IgG is shown. In A-D mean 
values± SD of triplicates are presented; significant (p<0.01) PMA-induced differences are indicated by *. 
However, after 48h PMA-treatment, all 3 lines had closed or nearly closed the wound. D6.1 
and anti-CD49d only inhibited migration of AS-Tpan8 cells. On the contrary, anti-CD49c 
most efficiently inhibited migration of AS and AS-Tpan8/CD9n cells (Fig.12A, B). AS, AS-
Tspan8 and AS-Tspan8/CD9n cells did not differ significantly in trans-well migration. 
However, only the migratory activity of AS-Tspan8 cells was strongly increased in the 
presence of PMA (Fig.12C). Importantly, cable formation on matrigel was completely 
prevented in AS-Tspan8/CD9n and AS-Tspan8/CD9c+n chimeras and was weakened in AS-
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Tspan8/CD151n chimeras as compared to AS-Tspan8 wild type cells. This accounted for the 
number of cable-forming cells as well as for the cable length (Fig.13A, B). 
 
Figure 12. Impact of the Tspan8 N-terminal region on cell migration: Migration of untreated and PMA-treated AS, 
AS-Tspan8 and AS-Tspan8/CD9n cells in a wound healing assay was evaluated after 24h and 48h by light microscopy. 
The impact of D6.1, anti-CD49c and anti-CD49d on wound healing was evaluated in PMA-treated cells after 48h. (A) 
Representative examples of images of wound healing in AS-Tspan8 and AS-Tspan8/CD9n cells. Black lines represent 
the initial scratch and the red dotted lines denote the migrated front. (B) The mean percentage of wound closure in 
dependence of the presence of PMA and antibodies of three independent experiments. (C) Mean values± SD of transwell 
migration of CFSE- labeled untreated and PMA-treated AS, AS-Tspan8 and AS-Tspan8/CD9n cells. (B & C) Significant 
differences (p<0.01) in dependence on PMA-treatment are indicated by * and in dependence on the presence of 
antibodies by s.  
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Thus, AS-Tspan8 cells responded to PMA-treatment with pronounced migration and reduced 
adhesiveness. Both activities were mitigated, when the N-terminal region was exchanged by 
that of CD9. 
 
Figure13. Impact of the Tspan8 N-terminal region on cable formation. AS-Tspan8 and AS-Tspan8-chimeras were 
seeded on matrigel. Cable formation and sprouting was evaluated after 24h by light microscopy. (A) Representative 
examples (scale bar: 20µm); (B) the mean numbers of cells forming cables and the relative mean± SD of cable length in 
10 independent areas. Significant differences (p<0.01) compared to AS-Tspan8 cells are indicated by *. 
Taken together, Tspan8 takes a selective route of internalization due to its association with 
INS2 and the recruitment of CD49d in the internalization complex. This selective 
internalization could well account for the functional activity of AS-Tspan8 exosomes 
provided the Tspan8 internalization complex is recovered in exosomes and contributes to 
target cell selection. Therefore, I started to explore the engagement of this internalization in 
exosome assembly and target cell selection. 
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3.6 Subpopulations within the AS-Tspan8 derived exosomes 
Since we had seen marked differences in the internalization of Tspan8 as compared to CD9 
and CD151, and the CD9-CD151-Tspan8 complex detected in the cell membrane of resting 
cells was not recovered after internalization, it seemed plausible that these differences may 
lead to sub-populations of exosomes deriving from the same cell, which differ in Tspan8 and 
CD9 content. To sort this, we incubated AS-Tspan8 and the AS-Tspan8-CD9n - derived 
exosomes with D6.1 or anti-CD9-coated latex beads. Tetraspanin expression of latex-bead-
bound positively selected population as well as non-bound exosome populations (after 
binding to nascent, non-coated latex beads) was evaluated by flow cytometry after 
incubations with D6.1 or anti-CD9 and with APC- conjugated secondary antibody.  
These, however, could not be verified. Exosomes binding to D6.1-coated beads were both- 
Tspan8 and CD9 positive and exosomes that did not bind to D6.1-coated beads were mostly 
CD9-
 









exosomes were recovered in the non-binding fraction (Fig.14). 
From these findings we concluded that during the process of formation of MVB, differences 
in the internalization of individual tetraspanins become, at least partly, hidden, which may be 
facilitated by the continuity of the process, such that distinctly internalized endosomes and 
endosomes derived from the synthetic pathway are concomitantly recovered after the 
collection period of 48h. Nonetheless, not all Tspan8 expressing exosomes could be captured 
by CD9-coated beads. 




Figure 14. Tetraspanin recovery in exosomes. DHPE-labeled, AS-Tspan8- and AS-Tspan8/CD9n- exosomes were 
incubated with D6.1- or anti-CD9-coated latex beads. Bound aa well as unbound exosomes (which were then loaded on 
native/ uncoated latex beads) were stained with D6.1 or anti-CD9 and counterstained with anti-mIgG-APC. (A) Examples; 




 exosomes are 
indicated by *. 




3.7   Differences in the tetraspanins webs  
In view of the latter finding, the existence of well- defined subpopulations of exosomes with 
respect to content of CD9 and Tspan8 seemed unlikely. On the other hand, there are 
remarkable differences in effects of AS, AS-Tspan8, ASML and AS-Tspan8-CD104 
exosomes on EC, where only AS-Tspan8 exosomes could activate ECs, as shown by others 
in our group (Gesierich et al., 2006; Nazarenko et al., 2010). Thus, we speculated that 
different tetraspanin-complexes on the exosomes account for the differences in target 
selection. 
I outlined above that Tspan8, distinct to CD9 and CD151, during the internalization process 
associates with CD49d, while, similar to CD9 and CD151, being preferentially associated 
with CD49c in the membrane of the resting cell. To find out if these differences among the 
tetraspanin-complexes generated during internalization were maintained in exosomes, we 
carried out immunoprecipitations against Tspan8, CD9, CD151 and CD81 on biotinylated 
and non-biotinylated AS-, AS-Tspan8-, AS-Tspan8/CD9n- and AS-Tspan8-CD104-
exosomes. After 10% SDS PAGE, western blotting with streptavidin-conjugated horse radish 
peroxidase (Strep-HRP) was performed with IPs done on biotinylated exosomes (Fig.15) 
and, silver staining was carried out with non-biotinylated samples to have an overview of 
differences in tetraspanin webs, if any.  
In fact, these differences in the tetraspanin-complexes generated during the internalization 
process were maintained in exosomes. Anti-CD49c precipitated Tspan8, CD9 and CD151 in 
AS-, AS-Tspan8-, AS-Tspan8/CD9n- and AS-Tspan8-CD104-exosomes. Instead, anti-
CD49d precipitated only Tspan8 and CD151 in AS-Tspan8-exosomes and Tspan8 in AS-
Tspan8-CD104 exosomes. B5.5 (anti-CD49f/CD104) also precipitated Tspan8 in AS-
Tspan8-CD104 exosomes (Fig.15A and 15B). 
As revealed by immunoprecipitations with anti-CD151, -CD9, -CD81 and -Tspan8 (D6.1), at 
least one additional protein was selectively precipitated by D6.1 and only in case of AS-
Tspan8 exosomes (Fig.15C and 15D). This and additional proteins selectively recovered in 
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the exosomes of AS, AS-Tspan8, AS-Tspan8/CD9n and AS-Tspan8-CD104 are currently being 
identified with MALDI- TOF analysis.                           
 
Figure 15. Recovery of tetraspanin complexes in exosomes: (A and B) AS, AS-Tspan8, AS-Tspan8/CD9n and AS-
Tspan8-CD104 exosomes were lysed with Brij96 and precipitated with anti-CD49c, anti-CD49d and B5.5 (anti-
CD49f/CD104). After SDS-PAGE separation and transfer, membranes were blotted with D6.1, anti-CD9 and anti-
CD151. Where indicated (B), exosomes were collected from PMA-stimulated AS-Tspan8 and AS-Tspan8-CD104 cells. 
(C) Exosomes from the cell lines indicated above were immunoprecipitated with D6.1, anti -CD9, anti-CD151 and anti-
CD81. Immunoprecipitates were separated by 10% SDS-PAGE and silver stained. The indicated bands were excised and 
analyzed by MALDI-TOF. (D) Immunoprecipitation with lysates of biotinylated exosomes samples done as in (C), 10% 
SDS-PAGE was run, followed by transfer to nitrocellulose membrane and blotting with streptavidin-HRP to get an 
overview of tetraspanin complexes. 
These findings confirmed that the exosomal tetraspanin web differs in dependence on the 
presence of Tspan8. In addition, Tspan8 web recruitment into exosomes also becomes 
affected by the available integrins. 
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3.8 Exosome binding to cells. 
Exosomes derived from AS, AS-Tspan8 and AS-Tspan8-CD104 have been shown to differ 
functionally (Gesierich, 2006; Nazarenko et al., 2010),  for e.g., AS-Tspan8 as compared to 
AS exosomes preferentially bound to and are taken up by endothelial cells (Nazarenko et al., 
2010). In addition, differences were seen in the tetraspanin complexes of the AS, AS-Tspan8, 
AS-Tspan8-CD9n and AS-Tspan8-CD104 derived exosomes. Thus, it became likely that the 
tetraspanin complexes on exosomes contribute to target cell selection. For this, it was 
imperative to first check whether exosomes indeed bind to different cells and tissues in vitro. 
 




Figure16. In vitro binding and uptake of exosomes by cell lines and hematopoietic cells. DHPE-labeled AS, AS-
Tspan8-, AS-Tspan8/CD9n- and AS-Tpan8-CD104-exosomes were incubated with (A)  RAEC, LuFb, LnStr, AS, AS-
Tspan8, AS-Tspan8/CD9n and AS-Tspan8-CD104 cells or (B and C) with freshly harvested BMC, SC, LNC, PEC and 
PBL. Exosome uptake was evaluated by flow cytometry. (C) Samples as in B were counterstained by the indicated 
antibodies. Exosome binding / uptake on marker
+
 cells was only evaluated for AS-Tspan8 exosomes. Cells in upper left 
quadrants have taken up exosomes or, are exosome
+
, cells in the lower right quadrant are marker
+
, and in the upper right 
quadrant represents cells that are marker
+
 and have taken up exosomes. 
 
When dye-labeled AS-, AS-Tspan8-, AS-Tspan8/CD9n- and AS-Tspan8-CD104 exosomes 
(20µg/ml) were incubated with endothelial cells (RAEC), lung fibroblasts (LuFb), lymph 
node stroma cells (LNstr) and the tumor lines AS, AS-Tspan8, AS-Tspan8/CD9n and AS-
Tspan8-CD104 exosome binding clearly differed depending on the exosome donor line and 
the target cell. Thus, AS-Tspan8- and AS-Tspan8/CD9n-exosomes were preferentially taken 
up by endothelial cells as well as by AS-Tspan8 and AS-Tspan8-CD104 tumor cells. Instead, 
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AS-exosomes preferentially bind LuFb, AS-Tspan8/CD9n and AS-Tspan8-CD104 cells. 
Distinctly, too, AS-Tspan8-CD104 exosomes strongly bind LNStr, AS and AS-Tspan8-
CD104 (Fig.16A). Similar studies were performed on freshly harvested hematopoietic cells 
(Fig16B). In vitro exosomes uptake by hematopoietic cells again differed with the source of 
the exosomes. BMC and LNC more readily took up AS-Tspan8-exosomes and AS-Tspan8-
CD104 exosomes also bound more strongly to LNC. As shown for AS-Tspan8 exosomes, 




 as well as by CD54
+
 cells. 








 cells was restricted to the 
origin of the hematopoietic cells and was mostly seen in PBL (Fig.16C). 




Figure 17. In-vivo  uptake of exosomes. 250ug of SP-Dio18 (3) labeled  AS, AS-Tspan8, AS-Tspan8/CD9n or AS-
Tspan8-CD104-exosomes were injected i.v. in the tails  of 9-11week old BDX rats. 24h after injection, rats were 
sacrificed, spleen cells (SC) were prepared from mincing spleen, peripheral blood mononuclear cells were obtained by 
Ficoll-Hypaque centrifugation gradient of heparinized blood, and peripheral exudate cells (PEC) were collected after 
washing the peritoneal cavity with PBS-heparin. These cells were then subjected to FACS to look for exosome signals. 
(A) Percentage of BMC, SC, PEC and PBL that had taken up exosomes are shown (mean± SD of 4 rats, significant 
differences are indicated by *). (B and C) Cells were counterstained with antibodies for the indicated markers. (B) 
Representative example (flow cytometry): cells in upper left quadrant are marker
+
, cells in the lower right quadrant are 





, and cells in the upper right quadrant took up exosomes and are  marker
+












grouped in negative (0-10%), weak co-staining (10<50%), distinct co-staining (50<70%), strong co-staining (70-90%) 









in comparison to AS exosomes is indicated by *. 
Particularly interesting was the question, especially on seeing the differences in the in vitro 
studies, whether exosomes will be taken up in vivo or will be captured after intravenous 
application in spleen and liver and become degraded.  For this, 250µg of SP-Dio18 (3) labeled 
AS, AS-Tspan8, AS-Tspan8/CD9n, and AS-Tspan8-CD104 exosomes were injected 
intravenously in the tail of 9-11wk old BDX rats. 24h later, the animals were sacrificed and 
blood, lymph nodes, thymus, spleen, pancreas, lung, liver, and bone marrow were excised. 
Peripheral blood leukocytes (PBL) were obtained via Ficoll-Hypaque gradient centrifugation. 
Parts of organs were frozen for immunohistological studies. Single cell suspension from 
organs were prepared and used for FACS analysis after staining with antibodies mentioned in 
Fig 17 and Fig.18.  
The analysis of exosomes recovered in distinct hematopoietic / lymphoid organs after 
intravenous application strongly argued against unspecific capture and elimination of 
exosomes. Distinct from the in vitro uptake, exosomes were preferentially recovered in PEC, 
followed by BMC, SC and, less abundantly, PBL. They were hardly recovered in LNC. The 
uptake of exosomes differed in dependence on their origin. BMC preferentially took up AS-, 
PEC AS-Tspan8- and AS-Tspan8/CD9n- and SC AS-Tspan8- and AS-Tspan8-CD104-
exosomes (Fig.17A). As demonstrated in Fig.17B and shown in detail in Fig17C, the target 
cell profile of leukocytes taking up in vivo the four types of exosomes differed. Fig.17C 
indicates the percentage of cells that express defined markers and have taken up exosomes. 
From there it became obvious that leukocytes expressing the tetraspanins CD63, CD81, 
CD151 and/or Tspan8 more readily take up AS-Tspan8 than AS exosomes. The same 
account for leukocytes expressing the integrin chains β1 (CD29), α6 (CD49f), β3 (CD61) 
















) than by CD4
+
 cells. They are rarely taken up by CD8
+
 cells. Uptake of 
AS-Tspan8/CD9n exosomes by hematopoietic cells does not differ significantly from that of 
AS-exosomes. AS-Tspan8-CD104-exosomes have only an advantage in uptake by some of 
the leukocyte subpopulations that also preferentially take up AS-Tspan8-exosomes.                   













Figure 18. In vivo binding/ uptake of exosomes by solid organs. Solid organs were excised from rats as described in Fig.16 
and were used for measuring the percentage of cells that took up exosomes, by flowcytometry of their single cell preparations 
(A), or shock frozen for histological studies (B). Sections were incubated with DAPI for nuclear staining (blue), and  analysed by 
confocal microscopy to look for exosome uptake in vivo. The exosome signals are seen in green (B & E). To show the location 
within the organs, examples of transmitted light images (overlaid with green exosome signal) are provided below the dark field 
images (scale bar: 20µm). (C) Representative examples (flow cytometry). Cells in the upper left quadrant are marker
+
, cells in 
the lower right quadrant are exosome
+
  and the cell in upper right quadrant are marker
+
 and have taken up exosomes. (D) Mean 











cells were grouped in negative (0-10%), weak co-staining (10<50%), distinct co-staining (50<70%), strong co-
staining (70-90%) and (nearly) complete co-staining (90<100%). (E) Confocal microscopy of sections from  pancreas and large 
blood vessels from rats receiving AS-Tspan8 exosomes. Sections were counterstained with the indicated antibodies and Cy3-
conjugated secondary antibody. Marker staining (red), exosome uptake (green) and digital overlays are shown. Yellow indicates 
co-localization of exosomes with the indicated marker (scale bar: 20µm). 
Surprisingly, 24h after intravenous application, exosomes were also recovered in solid 
organs, where striking differences were observed not only with respect to exosome uptake in 
general, but also with respect to the selectivity for distinct exosomes. Uptake/ binding by 
pancreas, liver and lung was evaluated by flow cytometry  and immunohistology (Fig. 18). 
Transmitted light images were taken to get an idea of the localization withing the tissues. 
AS-Tspan8 exosomes were most readily taken up/ bound by the pancreas, likely in the 
exocrine region, followed by the spleen in possibly the B cell areas, large vessels (likely by 
endothelial cells, as also for AS-Tspan8/CD9n- exosomes) and the mesentery (in the yet un-
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defined regions/cells). Few exosomes were recovered in the liver by possibly the kupffer 
cells, in the gut by, likely the crypt cells, and in kidney where they seem to be taken up by 
tubuli as shown with the help of transmitted light image overlaid with exosome signals in 
green (Fig18B). In the lung, exosomes seemed to bind to the tissue around the broncheoli and 
AS-, AS-Tspan8/CD9n-, and AS-Tspan8-CD104- exosomes were not taken up as readily. 
The most striking dfferences were seen in the large blood vessels, where different from AS-
Tspan8- and AS-Tspan8/CD9n- exosomes, AS exosomes could only be found in what 
appears to be the peri-vascular tissue and, AS-Tspan8-CD104 exosomes were not detected at 
all.  The latter were also not recovered in liver (Fig 18B). However, the precise regions/ cells 
which bind/ take up these exosomes in the tissues mentioned above have yet to be confirmed. 
In the first attempt to define the marker profile of cells taking up the distinct exosomes, 
isolated cells and tissue sections were counterstained with ICAM1, NCAM, PECAM and 
VCAM (CD106), as cells expressing these markers were found to have readily taken up 
exosomes according to flow cytometry analysis (Fig 18D). AS-Tspan8 exosomes were 
recovered in ICAM1
+





cells (Representive examples are shown in  Fig18E). 
Taken together, it was shown that intravenously applied exosomes could find their target 
cells throughout the whole organism. We also demonstrated for the first time that exosomal 
tetraspanin web is decisive for exosome uptake by selective target cells in vivo. These 
findings could possibly be the first step towards creating tailored exosomes for therapeutic 
drug delivery to selected target cells. 
 




Exosomes are important contributors to the tumor cell communication with the environment 
(Schorey and Bhatnagar, 2008; van Niel et al., 2006). We and previous colleagues 
experienced that exosomes delivered by a Tspan8 cDNA-transfected tumor line, which consti-
tutively expresses CD9 and CD151, promotes EC maturation and activation, which is initiated 
by exosomal Tspan8-associated CD49d binding to EC (Gesierich et al., 2006, Nazarenko et 
al., 2010). Based on this finding we asked, whether Tspan8, CD9 and CD151 recruitment into 
exosomes differs. Tspan8 internalization proceeds in a complex with INS2, clathrin and 
CD49d, but independent of CD9 and CD151. Besides the impact of AS-Tspan8-exosomes on 
EC, stimulation-induced internalization of a Tspan8-clathrin-INS2-CD49d complex is 
accompanied by loss in adhesiveness and pronounced motility.  
Having resolved the internalization complex for Tspan8, I went further to explore if the 
changed tetraspanin associations during internalization are maintained on exosomes and if 
they have a role in exosomal target selection. I confirmed the selective binding of Tspan8-
exosomes to endothelial cells and uncovered a strong prevalence for pancreatic cells. 
Importantly I show for the first time that exosomes applied in vivo are recovered in various 
organs throughout the body of the organism, and that the origin of the exosomes defines their 
targets. 
4.1 Contribution of INS2 to Tspan8-internalization 
Tspan8-internalization proceeds more rapidly than CD9- and slower than CD151-
internalization. This is the consequence of a particular rearrangement of the Tspan8-web in re-
sponse to stress, mimicked by PMA-treatment. 
Tetraspanins can become internalized via an internalization motif, expressed by the 
tetraspanin or its associated proteins. Since the membrane proximity of the Tspan8 sorting 
motif, likely does not allow AP complex-binding (Berditchevski and Odintsova, 2007), we 
expected Tspan8 to co-internalize with, albeit weakly associated CD151. However, CD151 
internalizes more rapidly than Tspan8 and the Tspan8-CD151 association becomes weaker on 
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PMA-treatment, which excludes Tspan8-internalization proceeding predominantly via 
CD151-association. 
Tspan8 associates with EWI-F, INS2 and CD13 (Claas et al., 2005; in prep.). Weak co-
immunoprecipitation of Tspan8 with CD13 becomes reduced during PMA-treatment 
excluding CD13 as the driver for internalization. EWI-F also associates with CD9 (Charrin et 
al., 2001; Claas et al., 2005) and remains CD9-associated during internalization, the 
association being far stronger than with Tspan8. Thus, it is unlikely that EWI-F contributes to 
Tspan8-internalization. In contrast, the weak Tspan8-INS2-association in resting cells is 
strengthened by PMA-treatment and Tspan8-, but not CD9- or CD151-internalization is 
severely impaired in AS-Tspan8-INS2
kd
 cells. INS2 interacts with the Tspan8 N-terminal 
region, Tspan8-internalization and co-immunoprecipitation with INS2 being strongly reduced 
after exchange of the N-terminal region including the first transmembrane pass. Intersectins 
contain SH3 and SH3A domains. SH3 domains interact with dynamin and synaptojanin 
(Yamabhai et al., 1998), where dynamin binding may regulate the fission process (Evergren et 
al., 2007, Koh et al., 2004). In fact, a dynamin inhibitor prevented Tspan8, but not CD9 
internalization. SH3A domains are additionally involved in the intermediate step of coated-pit 
constriction (Simpson et al., 1999). The INS2 Eps15 homology domains promote endocytosis 
(Koh et al., 2007). Thus, the Tspan8-INS2 association can well account for pronounced 
Tspan8-internalization. 
4.2 Tspan8-web rearrangement during PMA-treatment 
In the resting state CD9 also, though weakly, associates with INS2. Therefore, activation-
induced recruitment of additional molecules, which account for rearrangement of the Tspan8-
web and pronounced internalization, became likely. In AS-Tspan8 cells, CD9, CD151 and 
Tspan8 are associated with CD49c. Only after PMA-treatment, Tspan8 co-localizes / co-
immunoprecipitates with CD49d. In exosomes, Tspan8 is associated with CD49d, but not 
CD49c (Claas et al., 1998; Gesierich et al., 2005; Nazarenko et al., 2010). These findings 
suggested PMA-induced recruitment of CD49d in the Tspan8-web. Indeed, only after PMA-
treatment Tspan8-clathrin-INS2-CD49d complexes are recovered in lighter density fractions, 
where they even resist partial cholesterol-depletion, known to dislodge tetraspanins into 
denser sucrose fractions (Zhang et al., 2009). Thus, during PMA-treatment Tspan8 associates 
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with CD49d and remains clathrin-associated, clathrin-coated pits being prone for 
internalization and known to support tetraspanin internalization (Helle and Dubuisson, 2008; 
Pols and Klumperman, 2009; Xu et al., 2009). As the CD49d association, which requires the 
large extracellular Tspan8 loop (Baldwin et al., 2008; Gutierrez-Lopez et al., 2003; Zhang et 
al., 2001), was weak in AS-Tspan8/CD9n-chimeras, it becomes likely that Tspan8-
internalization requires both INS2 and CD49d, where CD49d possesses an internalization 
motif (Pandey, 2009).  
Internalized membrane microdomains are recruited into early endosomes from where they can 
proceed along different pathways (Cocucci et al., 2009; deGassart et al., 2004; Février and 
Raposo, 2004; Johnstone, 2006; Stahl and Barbieri, 2002). These pathways clearly differ 
between Tspan8 and CD9. Tspan8, distinct from CD9, is mainly recovered in early 
endosomes. It is also recovered in LAMP1
+
 vesicles, which can derive from late endosomes 
or the synthetic pathway (Chapuy et al., 2008; Lakkaraju and Rodriguez-Boulan, 2008). 
Because the Tspan8-CD49d complex is abundantly recovered in exosomes, although Tspan8 
does not associate with CD49d during biosynthesis (Claas et al., 2005), Tspan8 in Lamp1
+
 
vesicles likely belongs to the recycling pool. How Tspan8 becomes recruited in Lamp1
+
 
vesicles remains to be clarified. Finally, we suggest that the Tspan8-CD49d-association 
accounts for the different fate of internalized Tspan8 and CD9. Jones et al. (2006) described 
different routes of integrin recycling via a short and a long loop, where short loop recycling 
requires PKD1 downstream of Rab4. CD49d is shown to undergo rapid recycling (Rose, 
2006; Potapova et al., 2008). Our data points to CD49d-associated Tspan8 taking the short 
loop for release. 
Thus, activation-induced internalization (and exosome release) of Tspan8 depends on the 
association with INS2 and CD49d. As Tspan8-internalization is significantly retarded after 
INS2 silencing or exchange of the N terminal region, INS2 likely is involved in the fission 
process. A PMA-induced membrane microdomain re-organization promotes proximity 
between Tspan8 and CD49d, such that the CD49d internalization motif can facilitate 
recruitment into endosomes. 
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4.3 Pronounced Tspan8-CD49d-internalization impairs adhesion and 
promotes motility 
The particular route of PMA-induced Tspan8 internalization has functional consequences. As 
the internalization motif of the CD151 C-terminal tail could skew functional activities of AS-
Tspan8/CD151c-chimeras, only data on AS-Tspan8 and AS-Tspan8/CD9n are discussed. 
Tspan8-promoted FN- and Ln5-adhesion was abolished in AS-Tspan8/CD9n and strongly 
reduced in PMA-treated AS-Tspan8 cells. In line with these findings, D6.1 and anti-CD49d, 
but not anti-CD49c, became inefficient in blocking adhesion of PMA-treated AS-Tspan8 
cells. AS-Tspan8 cells / exosomes efficiently adhere to EC, binding being inhibited by D6.1 
and anti-CD49d, but not anti-CD49c (Nazarenko et al., 2010). In line with pronounced PMA-
initiated internalization of CD49d-associated Tspan8, PMA-treated AS-Tspan8 cells poorly 
adhered to EC and adhesion was inefficiently inhibited by D6.1 or anti-CD49d. 
Pronounced PMA-induced Tspan8-CD49d internalization is accompanied by increased mo-
tility, which depends on the intact Tspan8 N-terminal region. Anti-CD49d and D6.1, but not 
anti-CD49c inhibiting AS-Tspan8 migration strengthened the importance of the Tspan8-
CD49d-association. 
Internalization, recycling and/or release of exosomes are rapid processes such that, 
demonstrated for in vitro wound healing, PMA-initiated effects could vanish during a 
prolonged assay period. Therefore, cable formation was evaluated in the absence of PMA. 
Though the capacity for cable formation is maintained in AS-Tspan8/CD151- and -/CD9c-
chimeras, the majority of cells grow in clusters. AS-Tspan8/CD9n- and -/CD9c+n-chimeras 
largely lost cable formation capacity, which confirms the importance of the Tspan8 N-
terminal region for exhibiting morphogenic features. The underlying mechanism remains to 
be explored. 
AS-Tspan8-exosomes strongly promote EC maturation and activation (Nazarenko et al., 
2010) and, also advantageous for metastasizing tumor cells, Tspan8 internalization 
strengthens motility and cable formation. We here demonstrate that these Tspan8-selective 
activities rely on an activation-induced association of Tspan8 with INS2 and CD49d 
accompanied by a rearrangement of the Tspan8-web, where Tspan8 becomes recruited into 
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internalization-prone membrane microdomains. Elucidating the path of exosome generation 
clearly is one of the first steps in understanding exosome-target cell interaction. 
Exosomes are suggested to provide a most powerful therapeutic tool, owing to their capability 
of transferring functionally active proteins, mRNA and miRNA, which allows for striking 
target cell modulation (Denzer et al., 2000, Février and Raposo, 2004; Valadi et al., 2007, Iero 
et al., 2008). Accordingly, exosomes are suggested to provide a most powerful therapeutic 
tool (Viaud et al., 2010; Seow et al., 2009), which was confirmed in our lab. A rat tumor 
model where exosomes express Tspan8, sufficed for overshooting angiogenesis induction 
such that rats became moribund due to disseminated intravascular coagulation despite that the 
exosome delivering tumor was located subcutaneously (Claas et al., 1998). This demonstrates 
not only the power of exosomes, but also the danger posed by inappropriate exosome 
delivery. Appreciating the potential therapeutic as well as life threatening power of these 
particular vesicles (Porto-Carreiro, 2005; Vella et al., 2008) which are found in all body fluids 
(Mathivanan et al., 2010), it became demanding to explore, (i) whether exosomes use defined 
structures to bind to and fuse with target cells and (ii) whether exosomes require special 
ligands to recognize a potential target cell.  In the second part of my thesis I demonstrated that 
tetraspanins and tetraspanin-associated molecules are decisive for exosome binding and 
uptake. In addition, exosomes diffuse through the whole body, but are very selectively 
enriched in distinct cells / organs depending on their origin / tetraspanin-complex and 
apparently through the appropriate ligand expression of target cells / tissues. This exquisite 
selectivity of exosomes should, indeed, allow for their therapeutic use. 
4.4 The exosomal tetraspanin web 
The finding that the Tspan8 web is changing during internalization such that the association 
with CD9 and CD151 becomes weakened and that with CD49d strengthened, led us to 
suggest that individual cells may deliver a set of distinct exosomes. However, when exosomes 
became bound to latex beads via D6.1, the majority of exosomes bound and the remaining 




 exosomes. However, anti-CD9-





exosomes. From there we concluded that possibly due to the ongoing process of exosome 
generation by internalization as well as by vesicle formation during synthesis (Simons and 
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Raposo, 2009; Blanc et al., 2010) at least the majority of exosomes cannot be differentiated 
based on distinct tetraspanin expression. The large size difference between latex beads (4µm) 
and exosomes (0.03- 0.1µm), may provide an additional hindrance in the isolation of subtypes 
of exosomes via antibody-coated latex beads. Nonetheless, the subtle differences observed 
with anti-CD9-coated beads support our hypothesis that individual cells can deliver distinct 
exosomes.  
Exosomes are suggested to bind selective targets (Lakkaraju et al., 2008; Johnstone, 2006) 
and our group has shown before that this depends on exosomal tetraspanins (Gesierich et al., 
2006; Nazarenko, 2010). As we could not reliably separate exosome subtypes, it became 
likely that exosomes select for their target cell via tetraspanin-complexes, rather than via 
individual tetraspanins. This is well in line with tetraspanins acting as molecular facilitators 
that mostly modulate activity of associated molecules (Levy et al., 2005; Hemler, 2005). 
4.5 Exosome selectivity for target cells  
Exosomes express phosphatidylserine (PS) on their surface (Thery et al., 2002) which may 
provide an “eat me” signal (Schlegel et al., 2001) and has been suggested to act as the 
exosome binding receptor (Smalheiser, 2007; Simons and Raposo, 2009; Simpson et al., 
2009). However, it also has been shown that AnnexinV does not suffice to block exosome 
uptake by natural killer (NK) cells indicating that presence of phosphatidyl-serine alone is not 
sufficient for target cell binding (Keller et al., 2009) and requires additional signal. In fact, 
particularly the strong in vitro binding of exosomes to monocytes (CD11b
+
) in the peritoneal 
exudate suggests a contribution of scavenger receptors to exosome binding via phosphatidyl 
serine. However, the selectivity of exosome binding argues against a major role of PS in 
exosome uptake and, indeed, exosome uptake in vivo was not dictated by scavenger receptors. 
Thus, PS likely facilitates unspecific binding that may not be followed by exosome uptake. 
Exosomes derived from AS. AS-Tspan8, AS-Tspan8/CD9n and AS-Tspan8-CD104 cells, 
which differ only in Tspan8 and CD104 expression were tested in vitro for their selectivity of 
target cell binding. Clearly, these minor differences sufficed for distinct binding to 
hematopoietic cells, non-transformed and tumor cells. We confirmed the preferential binding 
of AS-Tspan8 exosomes to endothelial cells. Concerning hematopoietic cells, AS-Tspan8 
Discussion           89 
 
 
exosomes preferentially bound to BMC and LNC. In contrast, AS-derived exosomes have a 
selective advantage for LuFb; AS-Tspan8-CD104 exosomes preferentially bind LnStr, tumor 
cells and LNC. As demonstrated by the in vitro binding of AS-Tspan8 exosomes, these 
exosomes preferentially bind target cells expressing CD11b/CD18 (hematopoietic cells) or 
CD54, CD44, CD31 or CD62L (hematopoietic and endothelial cells). 
The more fascinating finding was the target cell selectivity of exosomes in vivo, where 
binding / uptake differed significantly for the 4 exosome preparations. First to note, the 
recovery of exosomes in vivo did not in all instances overlap with in vitro binding features, 
indicating that on the journey through the body, they become selectively trapped. In line with 
this, after i.v. injection, exosomes are not trapped in the first capillary bed. They are also not 
recovered preferentially in organs destined for degradation or release like spleen, liver and 
later on the kidneys. Instead, exosomes from the 4 lines have different preferences. AS-
Tspan8 exosomes are preferentially found in the pancreatic gland, the spleen and large 
vessels. Though AS-exosomes are also recovered in large vessels, it could be said from the 
morphology that they seemed to associate with different cells.  
In other organs, like the liver and the gut, few exosomes from all 4 lines are recovered. AS 
and, most pronounced AS-Tspan8-CD104 exosomes are also bound to broncheolar epithelial 





epithelial and mesenchymal cells preferentially take up exosomes. Co-localization as revealed 
by confocal microscopy pointed towards some of the molecules seen on cells taking up 
exosomes to be potentially the actual ligand(s).  
To address the question of ligand involved in exosome binding, studies via pull down assays 
are underway, where either cells or exosome lysates serve as matrix-bound catcher. This will 
allow the final proof of the engaged tetraspanin-complex receptors and their target cell 
ligands. Whether the exosomal tetraspanin web accounts for focalizing/ activating the receptor 
or whether tetraspanin, in addition, are involved in the internalization process remains to be 
explored. The latter could well be the case since, it has been suggested that the internalization 
process in the exosome donor cell and exosome uptake by target cell may follow the same 
fission/ fusion machinery (Ahmed and Xiang, 2010). If this is the case, the particular route of 
Tspan8 internalization may add to the selectivity of target cells. Still, the unexpected strong 
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organ selectivity in vivo requires additional experiments, as it becomes likely that chemokines 
/ chemokine receptors within the exosomes and the targeted tissue come into play. 
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5. Conclusion and Outlook 
Exosomes are most important intercellular communicators. It is known that exosomes 
abundantly express tetraspanins as one of their constitutive components. Tetraspanins, on the 
other hand, are known as molecular facilitators that modulate the activity of associated 
molecules and are involved in fusion and fission processes (Hemler, 2008). I here provided 
for the first time convincing evidence for exosomal activity of tetraspanins. 
First, tetraspanins, as demonstrated for Tspan8, are engaged in exosome composition via 
their route of internalization and the rearrrangment of their web of associating molecules. 
Notably, different tetraspanins use distinct paths of internalization. Furthermore, the 
available potential partnering molecules exert a considerable impact on exosome assembly 
and thereby on target cell selection. Extending the exploration of the internalization path to 
other tetraspanins and their associating molecules may greatly improve therapeutic efficacy 
of exosomes, e.g. in immunotherapy of cancer, where dendritic cell-derived exosomes are 
already in use as a potent means to induce a tumor antigen-specific T cell response (Viaud et 
al., 2010 ). 
Second, tetraspanins contribute to exosomal target cell selection. Selective targeting of 
exosomes has been suggested repeatedly (Belting and Wittrup, 2008; Mallegol et al., 2007; 
Schorey and Bhatnagar, 2008; Simons and Raposo, 2009), but has not yet been proven. 
Previous work in our group pointed towards tetraspanins (Tspan8) to be involved in the 
target cell selection process. I demonstrated that this is indeed the case, where the selectivity 
of exosome binding / uptake could be demonstrated most convincingly in vivo, where 
exosomes apparently reach their target cell throughout the body, irrespective of where they 
are generated. Again, the tetraspanin complexes appear to be the decisive element. The work 
for defining the ligands on various tissues and their partners in the tetraspanin complexes is 
underway and is being addressed by coupling lysates of exosomes to activated-sepharose 
matrix, which would „catch‟ the ligands from lysates of cells of interest when passed over the 
coupled matrix. In a reverse setting, molecules on exosomes that act like receptors for the 
target cell ligands can be identified. 
This knowledge will be helpful in generating tailored exosomes by equipping them with 
tetraspanin and associating receptors that allow to selectively target any cell type of interest 
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for therapeutic agent delivery. We are currently exploring this possibility in a model system 
of "tailored" exosomes delivered by non-transformed lung fibroblasts. Application of such 
exosomes compared to those from untransfected fibroblasts will provide answers to whether 
such tailored exosomes can specifically deliver any therapeutic message which could be 
cytotoxic drug, oncogene-suppressing miRNA, tumor growth suppressive agent, they carry to 
target cells. If our hypothesis holds true, it will prove to be a boon to therapeutics since, such 
an approach will have advantages of minimum cross- interaction with and harm to other 
cells. Use of tailored exosomes with defined specificity will not just be limited to field of 
cancer, but can also be applied for gene therapy of some genetic disorders like diabetes and 
cystic fibrosis and autoimmune diseases since they would be an ideal vehicle which will be 
non-toxic, stable in vivo and easily engineered. 
The observation that exosomes can transfer proteins, mRNA and miRNA to other cells that 
are functional in the new environment is exciting and heralds an unanticipated and until 
recently considered impossible mode of cell-cell communication, which creates hope for new 
most potent therapeutic options. I am confident that building on our previous work further 
unraveling the contribution of exosomal tetraspanins in physiological and pathological 
processes will provide valuable hints towards exosome-based therapeutics.
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6.  Summary 
 
Exosomes are deemed to be the most important intercellular communicators and tetraspanins 
/ tetraspanin-complexes are suggested to play an important role in exosomal target cell 
selection. It has been shown that only exosomes expressing a Tspan8-CD49d complex 
preferentially bind endothelial cells, which initiates angiogenesis. This finding was 
unexpected as in the exosome producing cells, Tspan8 is associated with CD49c and the 
tetraspanins CD9 and CD151. Considering the discussed therapeutic power of exosomes as 
message / drug transporter, it became important to clarify the mechanisms accounting for the 
distinct Tspan8 web in the cell membrane versus exosomes. We therefore compared the route 
of Tspan8 and Tspan8-chimera internalization, where the N- and/or C-terminal regions were 
exchanged with the corresponding regions of CD9 or CD151. 
Activation-induced Tspan8 internalization indeed proceeds more rapidly than CD9 
internalization and is accompanied by disassembly of the Tspan8-CD9-CD151 membrane 
complex found in the resting cells. Tspan8-internalization relies on the association of the 
Tspan8-N-terminal region with intersectin-2, part of a multimodular complex involved in 
clathrin-coated pit internalization. Internalization and recovery of Tspan8 in early endosomes 
is further promoted by the recruitment of CD49d such that only in PMA-activated cells a 
Tspan8-INS2-CD49d-clathrin complex is recovered in cholesterol depletion-resistant 
membrane microdomains. PMA-induced Tspan8-internalization promotes cell migration, but 
reduces matrix and cell adhesion.  
Suggesting that this particular route of Tspan8 internalization contributes to exosomal 
Tspan8 web as well as selective activities of Tspan8-expressing exosomes, I proceeded with 
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a comparative analysis of the exosomal tetraspanin web aiming for definition of exosomal 
target cells. 
Co-immunoprecipitation of cell lysates and exosomes from 4 rat tumor lines, AS, AS-
Tspan8, AS-Tspan8/CD9n and AS-Tspan8/CD104, which express CD9, CD81, CD151 and 
the CD49c and CD49d integrin chains, but differ by Tspan8 and CD104 integrin chain 
expression revealed that CD9, CD81 and CD151 preferentially associate with CD49c and, 
only CD151 with CD104 in cell lysates as well as exosomes. Instead, Tspan8 associated with 
CD49c in cell lysates, but with CD49d and CD104 in exosomes. The differences in 
complexes on exosomes severely influenced target cell selection in vitro and in vivo, where 
the latter revealed efficient exosome uptake in different hematopoietic compartments and 
solid organs after i.v. injection. Only exosomes expressing the Tspan8-CD49d complex 
preferentially integrated into endothelial cells and pancreatic tissue, exosomes expressing the 
CD151-CD104 or the Tspan8-CD104 complex were preferentially taken up by stromal cells 
in liver and lung, exosomes expressing CD9- or CD81-CD49c complexes were mostly 
recovered in hematopoietic cells.  
Taken together, we clarified the route of Tetraspanin8 internalization and showed that the 
changed associations created during internalization are maintained in exosomes. Moreover, 
the differences in tetraspanin complexes, which are evident from the point of internalization 
as well as in the exosomes, allow for the selectivity of exosomes towards target cells. These 
findings provide for the first time convincing evidence that exosomal tetraspanins contribute 
to target cell selection such that, according to the tetraspanin-complex on exosomes 
predictions can possibly be made on potential target cells. This knowledge will allow 
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